KR20210133603A - Composition for preventing or treating dementia comprising grub as active component - Google Patents
Composition for preventing or treating dementia comprising grub as active component Download PDFInfo
- Publication number
- KR20210133603A KR20210133603A KR1020200052411A KR20200052411A KR20210133603A KR 20210133603 A KR20210133603 A KR 20210133603A KR 1020200052411 A KR1020200052411 A KR 1020200052411A KR 20200052411 A KR20200052411 A KR 20200052411A KR 20210133603 A KR20210133603 A KR 20210133603A
- Authority
- KR
- South Korea
- Prior art keywords
- vitamin
- dementia
- composition
- preventing
- alzheimer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 84
- 206010012289 Dementia Diseases 0.000 title claims abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 28
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 16
- 201000004810 Vascular dementia Diseases 0.000 claims abstract description 15
- 241000237858 Gastropoda Species 0.000 claims description 29
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 24
- 244000078534 Vaccinium myrtillus Species 0.000 claims description 20
- 238000000855 fermentation Methods 0.000 claims description 20
- 230000004151 fermentation Effects 0.000 claims description 20
- 235000013305 food Nutrition 0.000 claims description 20
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 18
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 16
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 16
- 240000009088 Fragaria x ananassa Species 0.000 claims description 15
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 14
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 13
- 235000013376 functional food Nutrition 0.000 claims description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 12
- 229930003268 Vitamin C Natural products 0.000 claims description 12
- 235000021028 berry Nutrition 0.000 claims description 12
- 235000019156 vitamin B Nutrition 0.000 claims description 12
- 235000019154 vitamin C Nutrition 0.000 claims description 12
- 239000011718 vitamin C Substances 0.000 claims description 12
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 11
- 235000013824 polyphenols Nutrition 0.000 claims description 11
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 11
- 208000024891 symptom Diseases 0.000 claims description 11
- 239000011720 vitamin B Substances 0.000 claims description 11
- 235000017848 Rubus fruticosus Nutrition 0.000 claims description 10
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 10
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 10
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 10
- 235000021014 blueberries Nutrition 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 10
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 229920000855 Fucoidan Polymers 0.000 claims description 9
- 240000001890 Ribes hudsonianum Species 0.000 claims description 9
- 235000016954 Ribes hudsonianum Nutrition 0.000 claims description 9
- 235000001466 Ribes nigrum Nutrition 0.000 claims description 9
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 claims description 9
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 claims description 9
- 229930003316 Vitamin D Natural products 0.000 claims description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 9
- 235000003650 acai Nutrition 0.000 claims description 9
- 239000001905 cichorium intybus l. root extract Substances 0.000 claims description 9
- 235000004634 cranberry Nutrition 0.000 claims description 9
- 235000019166 vitamin D Nutrition 0.000 claims description 9
- 239000011710 vitamin D Substances 0.000 claims description 9
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 9
- 229940046008 vitamin d Drugs 0.000 claims description 9
- 244000063299 Bacillus subtilis Species 0.000 claims description 8
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 8
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 8
- 241000196324 Embryophyta Species 0.000 claims description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 8
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 8
- 239000004310 lactic acid Substances 0.000 claims description 8
- 235000014655 lactic acid Nutrition 0.000 claims description 8
- 210000002751 lymph Anatomy 0.000 claims description 8
- 229960003512 nicotinic acid Drugs 0.000 claims description 8
- 229960002477 riboflavin Drugs 0.000 claims description 8
- 229960003495 thiamine Drugs 0.000 claims description 8
- 229940011671 vitamin b6 Drugs 0.000 claims description 8
- 210000002826 placenta Anatomy 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 235000019159 vitamin B9 Nutrition 0.000 claims description 6
- 239000011727 vitamin B9 Substances 0.000 claims description 6
- 235000011034 Rubus glaucus Nutrition 0.000 claims description 5
- 235000009122 Rubus idaeus Nutrition 0.000 claims description 5
- 244000291414 Vaccinium oxycoccus Species 0.000 claims description 5
- 229930003451 Vitamin B1 Natural products 0.000 claims description 5
- 229930003779 Vitamin B12 Natural products 0.000 claims description 5
- 229930003471 Vitamin B2 Natural products 0.000 claims description 5
- 229930003537 Vitamin B3 Natural products 0.000 claims description 5
- 229930003761 Vitamin B9 Natural products 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 235000010374 vitamin B1 Nutrition 0.000 claims description 5
- 239000011691 vitamin B1 Substances 0.000 claims description 5
- 235000019163 vitamin B12 Nutrition 0.000 claims description 5
- 239000011715 vitamin B12 Substances 0.000 claims description 5
- 235000019164 vitamin B2 Nutrition 0.000 claims description 5
- 239000011716 vitamin B2 Substances 0.000 claims description 5
- 235000019160 vitamin B3 Nutrition 0.000 claims description 5
- 239000011708 vitamin B3 Substances 0.000 claims description 5
- 235000019158 vitamin B6 Nutrition 0.000 claims description 5
- 239000011726 vitamin B6 Substances 0.000 claims description 5
- 239000011787 zinc oxide Substances 0.000 claims description 5
- 244000144927 Aloe barbadensis Species 0.000 claims description 4
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 4
- 241000122821 Aspergillus kawachii Species 0.000 claims description 4
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 4
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 4
- 241000581835 Monodora junodii Species 0.000 claims description 4
- 240000007651 Rubus glaucus Species 0.000 claims description 4
- 240000001717 Vaccinium macrocarpon Species 0.000 claims description 4
- 235000011399 aloe vera Nutrition 0.000 claims description 4
- 235000021302 avocado oil Nutrition 0.000 claims description 4
- 239000008163 avocado oil Substances 0.000 claims description 4
- 235000008524 evening primrose extract Nutrition 0.000 claims description 4
- 229940089020 evening primrose oil Drugs 0.000 claims description 4
- 239000010475 evening primrose oil Substances 0.000 claims description 4
- 235000012661 lycopene Nutrition 0.000 claims description 4
- 239000001751 lycopene Substances 0.000 claims description 4
- 229960004999 lycopene Drugs 0.000 claims description 4
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 4
- 235000013557 nattō Nutrition 0.000 claims description 4
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 3
- 229930003756 Vitamin B7 Natural products 0.000 claims description 3
- 235000021324 borage oil Nutrition 0.000 claims description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 229940031439 squalene Drugs 0.000 claims description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 3
- 238000010257 thawing Methods 0.000 claims description 3
- 235000011912 vitamin B7 Nutrition 0.000 claims description 3
- 239000011735 vitamin B7 Substances 0.000 claims description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- 229930003571 Vitamin B5 Natural products 0.000 claims description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 2
- 229960002079 calcium pantothenate Drugs 0.000 claims description 2
- 239000011675 vitamin B5 Substances 0.000 claims description 2
- 235000009492 vitamin B5 Nutrition 0.000 claims description 2
- 244000307700 Fragaria vesca Species 0.000 claims 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 38
- 230000006870 function Effects 0.000 abstract description 15
- 201000006474 Brain Ischemia Diseases 0.000 abstract description 10
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract description 10
- 206010008118 cerebral infarction Diseases 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 206010051290 Central nervous system lesion Diseases 0.000 abstract description 7
- 230000001713 cholinergic effect Effects 0.000 abstract description 7
- 230000003412 degenerative effect Effects 0.000 abstract description 7
- 210000000653 nervous system Anatomy 0.000 abstract description 6
- 238000010171 animal model Methods 0.000 abstract description 5
- 230000000971 hippocampal effect Effects 0.000 abstract description 5
- 230000015654 memory Effects 0.000 abstract description 5
- 230000035045 associative learning Effects 0.000 abstract description 4
- 230000000007 visual effect Effects 0.000 abstract description 4
- 208000037259 Amyloid Plaque Diseases 0.000 abstract description 3
- 210000000274 microglia Anatomy 0.000 abstract description 3
- 230000004044 response Effects 0.000 abstract description 3
- 230000007596 spatial working memory Effects 0.000 abstract description 3
- 230000006931 brain damage Effects 0.000 abstract description 2
- 231100000874 brain damage Toxicity 0.000 abstract description 2
- 208000029028 brain injury Diseases 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 16
- 101150047834 SNAI2 gene Proteins 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 229940088594 vitamin Drugs 0.000 description 10
- 229930003231 vitamin Natural products 0.000 description 10
- 235000013343 vitamin Nutrition 0.000 description 10
- 239000011782 vitamin Substances 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 8
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 8
- 235000021029 blackberry Nutrition 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000001320 hippocampus Anatomy 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 7
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 7
- 229960004373 acetylcholine Drugs 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 7
- 102100033639 Acetylcholinesterase Human genes 0.000 description 6
- 108010022752 Acetylcholinesterase Proteins 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 235000019152 folic acid Nutrition 0.000 description 6
- 239000011724 folic acid Substances 0.000 description 6
- 229960000304 folic acid Drugs 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 229940022698 acetylcholinesterase Drugs 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 210000001168 carotid artery common Anatomy 0.000 description 5
- 210000004004 carotid artery internal Anatomy 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 238000011302 passive avoidance test Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 4
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 4
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 210000000269 carotid artery external Anatomy 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 3
- 229930003270 Vitamin B Natural products 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000010208 anthocyanin Nutrition 0.000 description 3
- 239000004410 anthocyanin Substances 0.000 description 3
- 229930002877 anthocyanin Natural products 0.000 description 3
- 150000004636 anthocyanins Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 210000000087 hemolymph Anatomy 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 229960003581 pyridoxal Drugs 0.000 description 3
- 235000008164 pyridoxal Nutrition 0.000 description 3
- 239000011674 pyridoxal Substances 0.000 description 3
- 235000008151 pyridoxamine Nutrition 0.000 description 3
- 239000011699 pyridoxamine Substances 0.000 description 3
- 235000008160 pyridoxine Nutrition 0.000 description 3
- 239000011677 pyridoxine Substances 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 235000019157 thiamine Nutrition 0.000 description 3
- 239000011721 thiamine Substances 0.000 description 3
- 235000021470 vitamin B5 (pantothenic acid) Nutrition 0.000 description 3
- 235000021467 vitamin B7(Biotin) Nutrition 0.000 description 3
- 229940046001 vitamin b complex Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 2
- 101150060184 ACHE gene Proteins 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 101000756400 Human T-cell leukemia virus 2 Protein Rex Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 206010027304 Menopausal symptoms Diseases 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- 102000015499 Presenilins Human genes 0.000 description 2
- 108010050254 Presenilins Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 2
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 2
- 230000007131 anti Alzheimer effect Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 235000013353 coffee beverage Nutrition 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 2
- 229960000305 enflurane Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 2
- 150000002216 flavonol derivatives Chemical class 0.000 description 2
- 235000011957 flavonols Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000007602 hot air drying Methods 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000035992 intercellular communication Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- LZXHHNKULPHARO-UHFFFAOYSA-M (3,4-dichlorophenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].C1=C(Cl)C(Cl)=CC=C1C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 LZXHHNKULPHARO-UHFFFAOYSA-M 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 1
- VVJYUAYZJAKGRQ-BGZDPUMWSA-N 1-[(2r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)C1 VVJYUAYZJAKGRQ-BGZDPUMWSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ADOHEWVFRZKRHE-UHFFFAOYSA-N 2-acetyloxyethyl(trimethyl)azanium Chemical compound CC(=O)OCC[N+](C)(C)C.CC(=O)OCC[N+](C)(C)C ADOHEWVFRZKRHE-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Amino-1-propanesulfonic acid Natural products NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 description 1
- CYWHLOXWVAWMFO-UHFFFAOYSA-N 3-sulfanyl-1h-pyridine-2-thione Chemical compound SC1=CC=CN=C1S CYWHLOXWVAWMFO-UHFFFAOYSA-N 0.000 description 1
- UHBAPGWWRFVTFS-UHFFFAOYSA-N 4,4'-dipyridyl disulfide Chemical compound C=1C=NC=CC=1SSC1=CC=NC=C1 UHBAPGWWRFVTFS-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 238000010175 APPswe/PSEN1dE9 Methods 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 235000008636 Bacillus subtilis subsp natto Nutrition 0.000 description 1
- 244000075779 Bacillus subtilis subsp natto Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 241000723343 Cichorium Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- ZSWXIMXLLJRVFT-HGUBBEBESA-O Cyanidin 3-(2G-xylosylrutinoside) Chemical compound OC1[C@@H](O)[C@@H](O)C(C)O[C@H]1OCC1[C@@H](O)C(O)C(O[C@H]2[C@@H](C(O)[C@H](O)CO2)O)[C@H](OC=2C(=[O+]C3=CC(O)=CC(O)=C3C=2)C=2C=C(O)C(O)=CC=2)O1 ZSWXIMXLLJRVFT-HGUBBEBESA-O 0.000 description 1
- USNPULRDBDVJAO-YRBSALHSSA-O Cyanidin 3-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](Oc2c(-c3cc(O)c(O)cc3)[o+]c3c(c(O)cc(O)c3)c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 USNPULRDBDVJAO-YRBSALHSSA-O 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 240000004638 Dendrobium nobile Species 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 241000723267 Diospyros Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- IFYOHQQBIKDHFT-FPBZMTDJSA-O Pelargonidin 3-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(-c3ccc(O)cc3)[o+]c3c(c(O)cc(O)c3)c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 IFYOHQQBIKDHFT-FPBZMTDJSA-O 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000012412 Presenilin-1 Human genes 0.000 description 1
- 108010036933 Presenilin-1 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 241001593968 Vitis palmata Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Chemical compound C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 230000002205 anti-dementic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- YTMNONATNXDQJF-UBNZBFALSA-N chrysanthemin Chemical compound [Cl-].O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 YTMNONATNXDQJF-UBNZBFALSA-N 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000008162 cooking oil Substances 0.000 description 1
- 210000005257 cortical tissue Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- ZPPQIOUITZSYAO-AOBOYTTNSA-O cyanidin 3-O-beta-D-sambubioside Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)CO1)O)O)CO)C1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 ZPPQIOUITZSYAO-AOBOYTTNSA-O 0.000 description 1
- USNPULRDBDVJAO-FXCAAIILSA-O cyanidin 3-O-rutinoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(=[O+]C3=CC(O)=CC(O)=C3C=2)C=2C=C(O)C(O)=CC=2)O1 USNPULRDBDVJAO-FXCAAIILSA-O 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 229920001968 ellagitannin Polymers 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229920002824 gallotannin Polymers 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010019465 hemiparesis Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229930005303 indole alkaloid Natural products 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229960001331 keracyanin Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- ALWKGYPQUAPLQC-UHFFFAOYSA-N neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- IFYOHQQBIKDHFT-ASZXTAQUSA-O pelargonidin 3-O-rutinoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(=[O+]C3=CC(O)=CC(O)=C3C=2)C=2C=CC(O)=CC=2)O1 IFYOHQQBIKDHFT-ASZXTAQUSA-O 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- -1 polyphenol compounds Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000010686 shark liver oil Substances 0.000 description 1
- 229940069764 shark liver oil Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L35/00—Food or foodstuffs not provided for in groups A23L5/00 – A23L33/00; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/10—Natural spices, flavouring agents or condiments; Extracts thereof
- A23L27/12—Natural spices, flavouring agents or condiments; Extracts thereof from fruit, e.g. essential oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 굼벵이를 활성 성분으로 포함하여 알츠하이머 치매, 혈관성 치매 등 퇴행성 뇌병변에 의한 치매를 예방 또는 치료하기 위한 신규한 조성물에 관한 것이다.The present invention relates to a novel composition for preventing or treating dementia caused by degenerative brain lesions such as Alzheimer's dementia and vascular dementia by including slugs as an active ingredient.
알츠하이머는 해마 및 피질부위에 아밀로이드 플라크(amyloid plaque) 및 신경섬유의 꼬임(neurofibrillay angle)을 가지는 것을 조직학적 특징으로 하는 질환으로(Neuron, 6, 487-498), 알츠하이머의 병인론에서 가장 중요한 과정은 비수용성의 베타-아밀로이드(β-amyloid, Aβ) 펩타이드의 축적과정이다. Alzheimer's is a disease characterized by histological features of amyloid plaques and neurofibrillay angles in the hippocampus and cortex (Neuron, 6, 487-498). The most important process in the pathogenesis of Alzheimer's is It is a process of accumulation of insoluble beta-amyloid (Aβ) peptides.
수용성의 베타아밀로이드 펩타이드에는 Aβ(1-40)와 Aβ(1-42)가 가장 많은데, Aβ(1-42)가 Aβ(1-40)에 비하여 아밀로이드 플라크로 응집되기 쉽기 때문에 더욱 독성이 높은 것으로 증명되었다(Acta Biolchm Pol, 52, 417-423) 이 외에도, 아밀로이드 전구체 단백질(APP), 프레세닐린(PS)-1, PS-2, 아포리포프로틴등의 유전자의 차이 및 산화적인 성이 알츠하이머의 병인론에 관여한다고 알려져 있는데(BBA, 2007, 285-297), 이는 각종 유전자 조작 동물, 를 들면 APP 발현 마우스를 이용하거나 독성의 Aβ 펩티드를 중추 투여하여 알츠하이머의 동물모델을 확립함으로써 확인된다.Among the water-soluble beta-amyloid peptides, Aβ(1-40) and Aβ(1-42) are the most abundant, and Aβ(1-42) is more toxic than Aβ(1-40) because it is more likely to aggregate into amyloid plaques. (Acta Biolchm Pol, 52, 417-423) In addition to this, differences in genes such as amyloid precursor protein (APP), presenilin (PS)-1, PS-2, apolipoprotein, and oxidative sex in Alzheimer's (BBA, 2007, 285-297), which is confirmed by establishing an animal model of Alzheimer's by using various genetically engineered animals, for example, APP-expressing mice or by centrally administering a toxic Aβ peptide.
비수용성의 Aβ의 축적에 따른 산화적인 손상은 알츠하이머의 주요한 병인론 중의 하나로 알려져 있으며, 알츠하이머 환자의 뇌조직에서 산화적인 손상지표의 증가(Neurochem Res 33, 450-458; Neurotox Rex 2, 67-168) 및 내인성 항산화계의 이상(Neurotox Rex 2, 167-168)이 보고되었고, 이러한 현상은 알츠하이머의 동물모델(Behav Brain Res, 155, 185-196; J Neurosci, 27, 5394-5404)에서도 보고되었다. Oxidative damage caused by the accumulation of insoluble Aβ is known as one of the major etiologies of Alzheimer's, and an increase in oxidative damage markers in brain tissue of Alzheimer's patients (Neurochem Res 33, 450-458; Neurotox Rex 2, 67-168) and endogenous antioxidant system abnormalities (Neurotox Rex 2, 167-168) have been reported, and this phenomenon has also been reported in animal models of Alzheimer's disease (Behav Brain Res, 155, 185-196; J Neurosci, 27, 5394-5404).
더불어, 이에 따른 해마 및 피질부위의 콜린성 계(cholinergic system)의 손상 및 기능저하가 알츠하이머의 특징적 증상인 인지기억능 저하에 기여한다(Neurology 51, S18-S29; Curr Alzheimer Res 1, 241-248).In addition, damage and deterioration of the cholinergic system in the hippocampus and cortex contributes to cognitive memory decline, a characteristic symptom of Alzheimer's (Neurology 51, S18-S29; Curr Alzheimer Res 1, 241-248). .
한편, 알츠하이머의 예방 또는 치료를 위한 종래 기술로서는, 한국공개특허공보 제10-20.05-0101537호에 알츠하이어병을 비롯한 아밀로이드β 관련질환의 치료를 위해서 3-아미노-1-프로판술폰산과 신경보호제 또는 신경영양제와의 병용투여가 개시되어 있으며, 한국공개특허공보 제 10-2012-48105호에는 우르소데옥시콜린산 및 은행잎 추출물을 배합함으로서 상승적인 알츠하이머의 치료효과를 갖는 약제학적 조성물이 개시되어 있다. On the other hand, as a prior art for the prevention or treatment of Alzheimer's, 3-amino-1-propanesulfonic acid and a neuroprotective agent or Co-administration with a neurotrophic agent is disclosed, and Korean Patent Application Laid-Open No. 10-2012-48105 discloses a pharmaceutical composition having a synergistic Alzheimer's therapeutic effect by combining ursodeoxycholic acid and ginkgo leaf extract.
이 외에도 알츠하이머 치료용 조성물 또는 의약용도에 관한 다양한 발명이 행해져 왔으나, 여전히 알츠하이머 치료에 유용한 다양한 약물의 개발이 요구되고 있다.In addition to this, various inventions related to compositions for treating Alzheimer's disease or pharmaceutical use have been made, but development of various drugs useful for Alzheimer's treatment is still required.
또한, 혈관성 치매는 대부분 뇌혈관 동맥경화에 의해 뇌의 여러 곳에 혈액공급이 부족하게 되어 뇌세포에 손상을 입음으로서 발생하므로, 그 치료제로는 뇌혈관에 작용하는 고혈압 치료제나 아스피린 또는 손상받은 뇌세포를 보호하는 약제를 이용하나 뚜렷한 효과를 보이지 않으며, 기존의 치매 치료제는 주로 아세틸콜린에스터라제 억제 효과만을 가지고 있으므로 혈관성 치매에도 치료효과를 나타내는 약제의 개발이 요구되고 있다.In addition, vascular dementia is mostly caused by damage to brain cells due to insufficient blood supply to various parts of the brain due to cerebrovascular arteriosclerosis. Although a drug that protects vascular dementia is used, it does not show a clear effect, and the existing dementia treatment mainly has an acetylcholinesterase inhibitory effect.
본 발명자들은 파킨슨병, 알츠하이머 치매, 혈관성 치매 등 퇴행성 뇌 병변에 대해 효능을 나타내는 약제를 개발하고자 하였다. 본 발명자는 예의 연구한 결과 굼벵이의 알츠하이머 치매, 혈관성 치매에 대한 효과를 확인하여 본 발명을 완성하였으며, 따라서 본 발명이 이루고자 하는 기술적 과제는 알츠하이머 치매, 혈관성 치매 등 퇴행성 뇌병변에 의한 치매를 예방 또는 치료하기 위한 신규한 조성물을 제공하는 것이다.The present inventors tried to develop a drug that exhibits efficacy against degenerative brain lesions such as Parkinson's disease, Alzheimer's dementia, and vascular dementia. The present inventor completed the present invention by confirming the effect of slugs on Alzheimer's dementia and vascular dementia as a result of intensive research. Therefore, the technical task of the present invention is to prevent dementia caused by degenerative brain lesions such as Alzheimer's dementia, vascular dementia, etc. To provide novel compositions for treatment.
상기 기술적 과제를 달성하기 위하여 본 발명은,The present invention in order to achieve the above technical problem,
굼벵이 건조 분말, 굼벵이 혈림프 및 굼벵이 발효액으로 이루어진 군에서 선택되는 어느 하나 이상을 활성성분으로 포함하는 치매의 예방 또는 증상 완화용 기능성 식품 조성물을 제공한다.It provides a functional food composition for preventing or alleviating symptoms of dementia, comprising, as an active ingredient, any one or more selected from the group consisting of slug dry powder, slug blood lymph, and slug fermented broth.
본 발명에 따른 치매의 예방 또는 증상 완화용 기능성 식품 조성물에 있어서, 상기 굼벵이 혈림프는 굼벵이를 바늘로 찔러 구멍을 내거나 굼벵이를 얼렸다가 해동시킨 다음 원심분리기에 장착하고 원심분리를 하여 얻어지는 상등액일 수 있다.In the functional food composition for preventing or alleviating symptoms of dementia according to the present invention, the slug blood lymph may be a supernatant obtained by puncturing slugs with a needle or freezing and thawing slugs, then mounting them in a centrifuge and centrifuging. have.
본 발명에 따른 치매의 예방 또는 증상 완화용 기능성 식품 조성물에 있어서, 상기 굼벵이 발효액은 굼벵이 또는 분쇄한 굼벵이를 물에 넣고 Bacillus subtilis var. natto 균주, Bacillus subtilis 균주 및 Aspergillus kawachii 균주로 이루어진 군에서 선택되는 어느 하나 이상의 균주를 접종하여 발효시킨 것일 수 있다.In the functional food composition for preventing or alleviating symptoms of dementia according to the present invention, the fermented slugs or pulverized slugs are put in water and Bacillus subtilis var. It may be fermented by inoculating any one or more strains selected from the group consisting of natto strains, Bacillus subtilis strains and Aspergillus kawachii strains.
본 발명에 따른 상술한 바와 같은 조성물은 치커리 뿌리 추출물을 더 포함할 수 있다.The composition as described above according to the present invention may further comprise a chicory root extract.
본 발명에 따른 상술한 바와 같은 조성물은The composition as described above according to the present invention
비타민 B1, 비타민 B2, 비타민 B3, 비타민 B5, 비타민 B6, 비타민 B7, 비타민 B9 및 비타민 B12로 이루어진 군에서 선택되는 어느 하나 이상의 비타민 B;any one or more B vitamins selected from the group consisting of vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B9, and vitamin B12;
비타민 C;vitamin C;
비타민 D;vitamin D;
산화아연;zinc oxide;
식물성 유산균;plant lactic acid bacteria;
치커리 뿌리 추출물;chicory root extract;
돼지 태반 추출물; 및pig placenta extract; and
아사이베리(Acaiberry), 스트로베리(Strawberry), 크랜베리(Cranberry), 라스베리(Rasberry), 블랙커런트(Blackcurrant), 블랙베리(Blackberry) 및 블루베리(Blueberry)로 이루어진 군에서 선택되는 어느 하나의 베리;를Acai berry (Acaiberry), strawberry (Strawberry), cranberry (Cranberry), raspberry (Rasberry), blackcurrant (Blackcurrant), blackberry (Blackberry) and any one berry selected from the group consisting of blueberry (Blueberry); cast
더 포함할 수 있다.may include more.
본 발명에 따른 상술한 바와 같은 조성물은The composition as described above according to the present invention
달맞이꽃 오일, 보리지 오일, 알로에베라, 스쿠알렌, 라이코펜, 아보카도오일, 후코이단, 석곡, 파인베리(백색딸기,뉴클레이클라본이라고도함) 및 풋사과 폴리페놀로 이루어진 군에서 선택되는 어느 하나 이상을 더 포함할 수 있다. Evening primrose oil, borage oil, aloe vera, squalene, lycopene, avocado oil, fucoidan, seokgok, pineberry (also called white strawberry, nucleclavone) and green apple polyphenols can do.
본 발명에 따른 상술한 바와 같은 조성물에 있어서, 상기 치매는 알츠하이머 치매 또는 혈관성 치매일 수 있다.In the composition as described above according to the present invention, the dementia may be Alzheimer's dementia or vascular dementia.
본 발명에 따른 조성물은 알츠하이머 모델 동물에서 공간 작동 기억력 증가, 시각 재인지 기억력 증가, 연합학습능력 증가, 해마의 콜린성 신경계 기능 향상, 미세아교세포(Microglia)의 Iba-1-IR 양성 반응 억제 및 아밀로이드 플라크의 생성 억제 효과가 우수한 것으로 나타나, 알츠하이머의 예방, 완화 및 치료에 매우 유용하며, 뇌허혈(cerebral ischemia)에 의해 유발되는 뇌손상 조직의 보호 효과를 보이고 있어 혈관성 치매의 예방 및 치료에도 활용할 수 있다.The composition according to the present invention increases spatial working memory, increases visual recognition memory, increases associative learning ability, improves hippocampal cholinergic nervous system function, suppresses Iba-1-IR positive response of microglia and amyloid in Alzheimer's model animals It has been shown to have an excellent effect of inhibiting the formation of plaque, so it is very useful for the prevention, alleviation and treatment of Alzheimer's, and it has a protective effect on brain damaged tissue caused by cerebral ischemia, so it can be used for the prevention and treatment of vascular dementia. .
따라서, 본 발명의 조성물은 알츠하이머 치매, 혈관성 치매 등 퇴행성 뇌병변에 의한 치매를 예방 또는 치료하기 위한 약학 조성물 또는 건강기능성 식품 조성물로 유용하게 사용될 수 있다.Therefore, the composition of the present invention can be usefully used as a pharmaceutical composition or a health functional food composition for preventing or treating dementia caused by degenerative brain lesions, such as Alzheimer's dementia and vascular dementia.
도 1 및 도 2는 본 발명에 따라 제조한 수용성 펩타이드 분말과 지방산 오일에 대하여 시험한 결과이다.
도 3은 알츠하이머병 모델 동물의 Y-미로 시험에서 대조군, 조성물 1 처리군, 조성물 2 처리군 및 조성물 3 처리군의 평가 결과를 나타낸 그래프이다.
도 4는 알츠하이머병 모델 동물의 신물체 인식시험에서 대조군, 조성물 1 처리군, 조성물 2 처리군 및 조성물 3 처리군의 평가 결과를 나타낸 그래프이다.
도 5는 알츠하이머병 모델 동물의 수동회피시험에서 대조군, 조성물 1 처리군, 조성물 2 처리군 및 조성물 3 처리군의 평가 결과를 나타낸 그래프이다.
도 6은 대조군, 조성물 1 처리군, 조성물 2 처리군 및 조성물 3 처리군의 해마(hippocampus) 및 대뇌피질(Cortex)에서의 콜린 아세틸트랜스퍼라제 활성(ChAT activity)의 측정 결과를 나타낸 그래프이다.
도 7은 대조군, 조성물 1 처리군, 조성물 2 처리군 및 조성물 3 처리군의 해마 및 피질에서의 아세틸콜린 수준(Achlevel)의 측정 결과를 나타낸 그래프이다.
도 8은 대조군, 조성물 1 처리군, 조성물 2 처리군 및 조성물 3 처리군의 해마 및 피질에서의 아세틸콜린 분해효소 활성(AchE activity)의 측정 결과를 나타낸 그래프이다.
도 9는 본 발명에 따른 조성물이 뇌허혈에 미치는 영향을 나타낸 도이다.1 and 2 are test results for the water-soluble peptide powder and fatty acid oil prepared according to the present invention.
3 is a graph showing the evaluation results of the control group, the
4 is a graph showing the evaluation results of the control group, the
5 is a graph showing the evaluation results of the control group, the
6 is a graph showing the measurement results of choline acetyltransferase activity (ChAT activity) in the hippocampus and cerebral cortex (Cortex) of the control group, the
7 is a graph showing the measurement results of acetylcholine levels (Achlevel) in the hippocampus and cortex of the control group, the
8 is a graph showing the measurement results of acetylcholinease activity (AchE activity) in the hippocampus and cortex of the control group, the
9 is a view showing the effect of the composition according to the present invention on cerebral ischemia.
이하 본 발명에 대하여 상세하게 설명하기로 한다.Hereinafter, the present invention will be described in detail.
본 발명은 본 발명은 굼벵이 건조 분말, 굼벵이 혈림프 및 굼벵이 발효액으로 이루어진 군에서 선택되는 어느 하나 이상을 활성성분으로 포함하는 알츠하이머 치매, 혈관성 치매 등 퇴행성 뇌병변에 의한 치매를 예방 또는 치료하기 위한 조성물을 제공한다.The present invention provides a composition for preventing or treating dementia caused by degenerative brain lesions, such as Alzheimer's dementia and vascular dementia, comprising as an active ingredient any one or more selected from the group consisting of slug dry powder, slug blood lymph, and slug fermented broth. provides
본 발명에 따른 조성물은 알츠하이머 모델 동물에서 공간 작동 기억력 증가, 시각 재인지 기억력 증가, 연합학습능력 증가, 해마의 콜린성 신경계 기능 향상, 미세아교세포(Microglia)의 Iba-1-IR 양성 반응 억제 및 아밀로이드 플라크의 생성 억제 효과가 우수한 것으로 나타나, 알츠하이머의 예방, 완화 및 치료에 매우 유용하며, 뇌허혈(cerebral ischemia)에 의해 유발되는 뇌손상 조직의 보호 효과를 보이고 있어 혈관성 치매의 예방 및 치료에도 활용할 수 있다.The composition according to the present invention increases spatial working memory, increases visual recognition memory, increases associative learning ability, improves hippocampal cholinergic nervous system function, suppresses Iba-1-IR positive response of microglia and amyloid in Alzheimer's model animals It has been shown to have an excellent effect of inhibiting the formation of plaque, so it is very useful for the prevention, alleviation and treatment of Alzheimer's, and it has a protective effect on brain damaged tissue caused by cerebral ischemia, so it can be used for the prevention and treatment of vascular dementia. .
본 발명에서 사용되는 굼벵이는 한방으로부터 오랫동안 다양한 질환에 약으로 사용돼 왔으며 현재 농가에서 널리 사육돼 한방이나 민간요법에 사용되고 있으며 딱정벌레목(Coleopteran), 꽃무지과(Etonian) 곤충인 흰점박이꽃무지(Protaetia brevitarsis)의 유충을 의미한다.The slug used in the present invention has been used as a medicine for various diseases from oriental medicine for a long time, and is now widely bred in farms and used in oriental medicine or folk remedies. brevitarsis) larvae.
이와 같은 굼벵이의 일반 성분은 단백질 58% 정도 매우 높으며, 또한 불포화 지방산을 다량 함유하고 있는데 특히 혈압강하작용 등이 알려진 올레인산(oleic acid) 가 전체 지방산 중에서 60%를 차지하며, 무기질 중 인과 칼륨, 비타민은 B3와 B9이 포함되어 있어 독소를 없애주고 혈액순환을 원활하게 하는 효능이 있으며, 알레르기 중상을 완화시키며 혈액 생성을 돕는 유아기 필수 아미노산인 히스티딘(histidine), 인지능력 개선 및 기억력 향상에 도움이 되는 글루탐산(glutamic acid) 및 콜라겐 형성에 도움을 주어 연골형성을 돕는 프롤린(proline)이 이 다량 함유되어 있다.The general component of such slugs is very high about 58% of protein, and also contains a large amount of unsaturated fatty acids. In particular, oleic acid, which is known for its blood pressure lowering effect, accounts for 60% of the total fatty acids, and among minerals, phosphorus, potassium, and vitamins. Silver contains B3 and B9, which has the effect of removing toxins and smoothing blood circulation. Histidine, an essential amino acid for infancy that relieves severe allergy and helps blood formation, helps improve cognitive ability and improves memory. It contains a large amount of glutamic acid and proline, which helps to form cartilage by helping to form collagen.
또한, 굼벵이는 민간에서 간질환 치료제로 애용된 생약으로, 국내에서 굼벵이의 간보호 효과가 과학적으로 검증되었다. 굼벵이 추출물의 간 보호 효과는 사염화탄소 유발 급성 간염에서 GOT, GPT, 담즙산, 빌리루빈 수치가 조사하여 국립농업과학원에서 시험용 쥐에 굼벵이 추출액을 투여한 결과 간경화 예방 효과가 있다는 사실이 확인하였다. 간경화가 진행 중인 쥐에서 간섬유화를 억제하는 현상이 나타나 치료제로서도 효과가 있을 것으로 보고 있다. In addition, slugs are a herbal medicine used as a treatment for liver disease in the private sector, and the liver protection effect of slugs has been scientifically verified in Korea. GOT, GPT, bile acid, and bilirubin levels were investigated for the hepatoprotective effect of Slugfish extract in acute hepatitis induced by carbon tetrachloride. It has been shown to inhibit liver fibrosis in mice with liver cirrhosis, and is expected to be effective as a therapeutic agent.
이와 같은 굼벵이는 분말 형태로 본 발명에 따른 조성물에 사용될 수 있으며, 분말 제조 방법은 본 발명이 속하는 기술 분야에 널리 알려진 것이라면 특별한 제한 없이 이용 가능하며, 그 예로 굼벵이 건조 분말을 제조하기 위한 바람직한 방법은 제조하기 전에 굼벵이를 절식시켜, 바람직하게는 4일 정도 절식시켜 굼벵이의 내장 속에 남아 있는 노폐물을 완전히 제거한 후에 물을 끓여 약 5 내지 20초간 데쳐 굼벵이 표면에 대한 살균 효과 및 잡내를 제거한 다음에 40 ~ 60℃에서 건조(열풍 건조 또는 히터에 의한 건조, 동결 건조 모두 가능)하여 분말로 제조하는 방법에 의해 제조하는 것이다. Such slugs can be used in the composition according to the present invention in powder form, and the powder manufacturing method can be used without any particular limitation as long as it is widely known in the art to which the present invention pertains. For example, a preferred method for manufacturing slug dry powder is Fasting the slugs before manufacturing, preferably for about 4 days to completely remove the wastes remaining in the intestines of the slugs. It is manufactured by a method of drying at 60° C. (hot air drying, drying by a heater, freeze drying are all possible) and manufacturing a powder.
본 발명에서는 굼벵이에서 채취한 굼벵이 혈림프를 이용할 수도 있으며, 혈림프 채취 방법은 본 발명이 속하는 기술 분야에 널리 알려진 것이라면 특별한 제한 없이 이용 가능하며, 그 예로 세척한 굼벵이를 바늘로 찔러 구멍을 내거나 굼벵이를 얼렸다가 해동시킨 다음 원심분리기에 장착하고 원심분리를 한 후에 상등액을 취하여 굼벵이로부터 빠져나온 혈림프를 채취하는 방법이다. In the present invention, slug blood lymph collected from slugs can be used, and the blood lymph collecting method can be used without particular limitation as long as it is widely known in the art to which the present invention pertains. After freezing and thawing, it is installed in a centrifuge, and after centrifugation, the supernatant is taken to collect the blood lymph from the slugs.
또한, 본 발명에서는 액상의 혈림프를 분말로 제조하여 사용할 수 있는데, 이 경우 다양한 방법이 있으나 본 발명에서는 채취한 혈림프를 동결건조하여 분말로 제조하는 혈림프 분말 제조 단계를 포함하는데 이는 동결건조하여 분말로 하는 경우 다공성 비결정질 분말이 제조되어 다시 액상으로 녹일 때 손쉽게 녹일 수 있으며, 적정한 부피를 가지는 분말로 제조되어 다양한 용도로 사용할 수 있기 때문이다. 여기서 동결건조 방법은 본 발명이 속하는 기술 분야에 널리 알려진 것이라면 특별한 제한 없이 이용 가능하다.In addition, in the present invention, liquid hemolymph can be prepared and used as a powder. In this case, there are various methods, but the present invention includes the step of preparing a hemolymph powder by freeze-drying the collected hemolymph to produce a powder, which is freeze-dried. This is because when a porous amorphous powder is prepared and dissolved again in a liquid phase, it can be easily dissolved, and it can be used for various purposes by being prepared as a powder having an appropriate volume. Here, the freeze-drying method can be used without particular limitation as long as it is widely known in the art to which the present invention pertains.
본 발명에서 적용 가능한 굼벵이의 다른 이용 형태는 굼벵이 또는 분쇄한 굼벵이를 물에 넣고 Bacillus subtilis var. natto 균주, Bacillus subtilis 균주 및 Aspergillus kawachii 균주로 이루어진 군에서 선택되는 어느 하나 이상의 균주를 접종하여 발효시킨 발효액을 사용하는 것이다.Another use form of slugs applicable in the present invention is to put slugs or pulverized slugs in water and Bacillus subtilis var. natto strain, Bacillus subtilis strain and Aspergillus kawachii strain is to use any one or more strains selected from the group consisting of inoculated and fermented fermentation broth.
상술한 발효액에는 지방산 오일을 함유하는 상층부의 유상과 수용성 펩타이드를 함유하는 하층부의 수상으로 이루어져 있으며 이를 함께 본 발명에서는 사용하며, 필요에 따라서는 분리하여 개별적으로 사용할 수도 있고 양을 조절하여 사용할 수도 있다.The above-mentioned fermentation broth consists of an oil phase in the upper layer containing fatty acid oil and an aqueous phase in the lower layer containing water-soluble peptides, which are used together in the present invention, and may be used separately or by adjusting the amount if necessary. .
상기 발효에서 사용되는 굼벵이는 살아 있는 것, 죽은 것, 건조한 것 특별한 제한 없이 사용이 가능하며, (물을 사용하는 것은 발효가 효율적으로 이루어지도록 굼벵이 내로 수분을 충분히 함습시키기 위함이며, 물의 양은 굼벵이 충분히 잠길 수 있도록 넣어 주면 되며 특별한 제한이 있는 것은 아니다.The slugs used in the fermentation can be used without any particular limitation, whether they are live, dead or dry (the use of water is to sufficiently moisten the slugs so that the fermentation can be performed efficiently, and the amount of water is sufficient for the slugs to You can put it so that it can be locked, and there is no special limitation.
상기 발효를 위한 발효 온도는 발효를 진행하기에 적당한 온도이면 무방하며, 바람직하게는 상온에서 발효를 진행하는 것이며, 발효 시간은 특별한 제한은 없으나 5 내지 50시간 정도이다. 본 발명에서의 발효는 과 발효가 되어도 무방하기 때문에 균주의 접종량은 발효될 수 있는 충분한 양을 접종하면 되나, 효율성을 고려하면 사용한 굼벵이 중량 대비 약 2 내지 15중량%로 하는 것이 바람직하다.The fermentation temperature for the fermentation may be any suitable temperature to proceed with the fermentation, preferably, the fermentation is performed at room temperature, and the fermentation time is not particularly limited, but is about 5 to 50 hours. Since the fermentation in the present invention can be over-fermented, the inoculation amount of the strain may be inoculated with a sufficient amount to be fermented, but in consideration of efficiency, it is preferable to set it to about 2 to 15% by weight relative to the weight of the used slugs.
본 발명에 따른 발효가 진행이 되면 발효가 진행되면 점차 상층부쪽으로는 유상이 용출 분리되며 하층부는 굼벵이의 발효가 진행되어 형체가 사라지며 수상에 용해된다. 따라서 발효의 종결 시점은 굼벵이의 형체가 사라지는 시점까지로 하면 되며. 본 발명에서는 발효 균주로 Bacillus subtilis var. natto 균주, Bacillus subtilis 균주 및 Aspergillus kawachii 균주로 이루어진 군에서 선택되는 어느 하나 이상의 균주를 선택하였는데 이는 다양한 균주로 테스트해 본 결과 가장 본 발명의 목적에 맞는 균주를 선택한 것이다.When the fermentation according to the present invention proceeds, the oil phase gradually elutes and separates toward the upper layer as the fermentation proceeds, and the lower layer undergoes fermentation of the slugs, disappears and dissolves in the aqueous phase. Therefore, the end of fermentation can be done until the time when the shape of the slugs disappears. In the present invention, as a fermentation strain, Bacillus subtilis var. One or more strains selected from the group consisting of natto strains, Bacillus subtilis strains and Aspergillus kawachii strains were selected. As a result of testing with various strains, the strain most suitable for the purpose of the present invention was selected.
상술한 바와 같이 제조된 지방산 오일과 수용성 펩타이드는 피로회복, 혈당강화, 항치매, 항당뇨, 항산화, 간기능 개선, 노화 방지 등의 효능을 가지는 의약품, 건강 식품, 화장품 조성물의 활성 성분으로 사용되는데 매우 유용하다.The fatty acid oil and water-soluble peptide prepared as described above are used as active ingredients in pharmaceuticals, health foods, and cosmetic compositions having effects such as fatigue recovery, blood sugar strengthening, anti-dementia, anti-diabetes, antioxidant, liver function improvement, and anti-aging. Very useful.
또한, 종래의 용매추출은 용매를 이용한 추출 시 완벽한 용매 제거가 어려우며(잔류 용매 잔존), 고온 증류 처리로 인한 산패(과산화물가, 유리 지방산 증가)가 진행돼 품질이 저하되며, 또한 종래의 초임계추출은 추출율이 낮으며, 생산 단가가 매우 높아 경제적인 상용화가 어려우나 본 발명에 따른 발효 추출은 잔류 용매가 존재하지 않고, 저온 처리로 인한 생리 활성 물질의 과산화물가 및 산가가 낮으며, 발효에 의한 독성 물질의 제거 효과가 있다.In addition, in the conventional solvent extraction, it is difficult to completely remove the solvent (residual solvent residual) during extraction using a solvent, and rancidity (peroxide value, free fatty acid increase) due to high-temperature distillation treatment progresses, which leads to deterioration of quality, and also the conventional supercritical extraction Silver extraction rate is low and production cost is very high, making it difficult to commercialize economically, but fermentation extraction according to the present invention does not contain residual solvents, has low peroxide and acid values of physiologically active substances due to low-temperature treatment, and toxic substances from fermentation has the effect of removing
본 발명에 따라 제조한 수용성 펩타이드 분말과 지방산 오일에 대하여 시험을 하여 그 결과를 도 1 및 도 2에 첨부하였으며 첨부된 도 1와 도 2를 보면 본 발명의 우수성을 확인할 수 있는데, 특히 수용성 펩타이드 분말은 트레오닌, 트립토판, 발린, 페닐알라닌, 티로신, 히스티딘, 이소로이신, 로이신, 라이신, 메치오닌, 시스틴 등의 필수아미노산은 물론 비필수아미노산 11종도 있으며,프로테신이라는 천연항생물질. 인돌알카로이드라는 혈행개선, 뇌졸중, 치매, 고지혈, 콜레스테롤감소 등 어혈을 풀어주는 물질 등. 당뇨치료. 간기능 개선, 항암, 항비만, 근감소증, 근무력증 등 여러 효능을 보이는 물질을 포함하고 있다/The water-soluble peptide powder and fatty acid oil prepared according to the present invention were tested and the results are attached to Figs. 1 and 2, and the superiority of the present invention can be confirmed by looking at the attached Figs. There are 11 non-essential amino acids as well as essential amino acids such as threonine, tryptophan, valine, phenylalanine, tyrosine, histidine, isoleucine, leucine, lysine, methionine, and cystine, and a natural antibiotic called protecin. Indole alkaloid, a substance that improves blood circulation, relieves eohyeol, such as stroke, dementia, hyperlipidemia, and cholesterol reduction. diabetes treatment. Contains substances showing various effects such as liver function improvement, anticancer, anti-obesity, sarcopenia, myasthenia gravis
또한, 본 발명에 따른 조성물은 치커리 뿌리 추출물을 더 포함할 수 있다.In addition, the composition according to the present invention may further include chicory root extract.
또 다른 실시예로서 본 발명에 따른 조성물은 비타민 B1 (티아민), 비타민 B2 (리보플래빈), 비타민 B3 (나이아신, 니코틴아마이드), 비타민 B5 (판토텐산), 비타민 B6 (피리독신, 피리독살, 피리독사민), 비타민 B7 (바이오틴), 비타민 B9 (폴산, 엽산) 및 비타민 B12 (코발라민)로 이루어진 군에서 선택되는 어느 하나 이상의 비타민 B;In another embodiment, the composition according to the present invention comprises vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B3 (niacin, nicotinamide), vitamin B5 (pantothenic acid), vitamin B6 (pyridoxine, pyridoxal, pyridoxamine). ), vitamin B7 (biotin), vitamin B9 (folic acid, folic acid) and vitamin B12 (cobalamin) any one or more vitamin B selected from the group;
비타민 C;vitamin C;
비타민 D;vitamin D;
산화아연;zinc oxide;
식물성 유산균;plant lactic acid bacteria;
치커리 뿌리 추출물;chicory root extract;
돼지 태반 추출물; 및pig placenta extract; and
아사이베리(Acaiberry), 스트로베리(Strawberry), 크랜베리(Cranberry), 라스베리(Rasberry), 블랙커런트(Blackcurrant), 블랙베리(Blackberry) 및 블루베리(Blueberry)로 이루어진 군에서 선택되는 어느 하나의 베리;를Acai berry (Acaiberry), strawberry (Strawberry), cranberry (Cranberry), raspberry (Rasberry), blackcurrant (Blackcurrant), blackberry (Blackberry) and any one berry selected from the group consisting of blueberry (Blueberry); cast
더 포함할 수 있다.may include more.
상기 뿌리 치커리는 국화과의 일종으로 주요성분은 이뉼린, 자당, 셀룰로우즈, 단백질, 회분 등으로 이루어져 있으며 유럽에서는 굵은 뿌리를 건조시켜 가루로 만들어 커피대용의 음료로 이용하거나 커피의 색 및 쓴맛을 짙게 하는 첨가제로 사용하기도 하며, 뿌리를 이뇨, 정장, 건위 및 피를 맑게 하는 민간약으로 이용한다.The root chicory is a kind of Asteraceae, and the main components are inulin, sucrose, cellulose, protein, ash, etc. In Europe, the coarse roots are dried and powdered to be used as a coffee substitute or to reduce the color and bitter taste of coffee. It is also used as an additive for thickening, and the root is used as a folk medicine for diuresis, intestinal tract, dry stomach and purifying blood.
상기 돼지 태반 추출물은 새끼와 모체의 자궁을 연결하는 기관으로, 새끼의 성장에 필요한 산소 및 각종 영양소를 공급하는 기능은 물론 새끼에 필요한 호르몬 생성과 면역력 증강에 필요한 인자의 합성 등 태아의 성장을 위해 다양한 기능을 담당하고 새끼가 출생하면 태반은 그 기능을 다하고 모체로부터 배출되는데, 이러한 태반은 각종 아미노산, 활성 펩타이드, 비타민, 미네랄, 효소 및 다양한 성장인자와 같은 풍부한 유효성분을 함유하고 있는 태반의 추출물이며, 태반 추출물에 다량 존재하는 아미노산은 생명의 근원으로 조직 형성 및 생체내 화학 반응 조절인자로서 다양한 생리기능이 있으며, 미네랄의 경우 세포내 대사 작용 및 혈액과 체액의 조정에 여러 작용을 하고, 지방산은 세포의 형성에 중요한 요소이다. 최근 다양한 바이오 연구에 의해 항산화, 항염증 작용, 상처 치료효과, 미용, <5> 피로회복, 면역 증강, 체질 개선, 조혈작용 등 폭넓은 기능을 하는 것으로 밝혀지고 있다.The pig placenta extract is an organ that connects the pups and the mother's uterus, and for the growth of the fetus, such as the function of supplying oxygen and various nutrients necessary for the growth of the pups, as well as the synthesis of factors necessary for the generation of hormones and immunity enhancement necessary for the pups. It is responsible for various functions, and when the offspring are born, the placenta fulfills its functions and is excreted from the mother. This placenta extract contains abundant active ingredients such as various amino acids, active peptides, vitamins, minerals, enzymes and various growth factors. Amino acids present in large amounts in placental extracts are the source of life and have various physiological functions as tissue formation and in vivo chemical reaction regulators. is an important factor in cell formation. Recently, various bio-researches have revealed that it has a wide range of functions, such as antioxidant, anti-inflammatory action, wound healing effect, beauty, fatigue recovery, immune enhancement, constitution improvement, and hematopoietic action.
상기 비타민 B 복합체( - 複合體, 영어: vitamin B complex) 또는 비타민 B군( - 群)은 세포 대사에서 중요한 역할을 수행하는 수용성 비타민들이다. 비타민 B는 한때 단일한 비타민으로 알려졌었으나, 이 후의 연구에서 비타민 B군은 같은 음식에서 종종 공존하지만 화학적으로 구별되는 비타민들이라는 것이 밝혀졌다. 일반적으로 보충제는 비타민 B 복합체(vitamin B complex)라고 불리는 8개 비타민 모두를 포함하고 있다. 개별적인 비타민 B 보충제는 각 비타민의 구체적인 이름으로 불린다.The vitamin B complex (-複合体, English: vitamin B complex) or vitamin B group (- 群) are water-soluble vitamins that play an important role in cellular metabolism. B vitamins were once known as a single vitamin, but later research has shown that the B vitamins are chemically distinct vitamins that often coexist in the same food. Typically, supplements contain all eight vitamins called the vitamin B complex. Individual B vitamin supplements are called by specific names for each vitamin.
비타민 B1 (티아민)Vitamin B1 (thiamine)
비타민 B2 (리보플래빈)Vitamin B2 (riboflavin)
비타민 B3 (나이아신, 니코틴아마이드)Vitamin B3 (niacin, nicotinamide)
비타민 B5 (판토텐산)Vitamin B5 (pantothenic acid)
비타민 B6 (피리독신, 피리독살, 피리독사민)Vitamin B6 (pyridoxine, pyridoxal, pyridoxamine)
비타민 B7 (바이오틴) (비타민 H라고도 한다)Vitamin B7 (biotin) (also known as vitamin H)
비타민 B9 (폴산, 엽산) (비타민 M이라고도 한다)Vitamin B9 (folic acid, folic acid) (also called vitamin M)
비타민 B12 (코발라민)Vitamin B12 (Cobalamin)
본 발명은 이와 같은 비타민 B 복합체 중 어느 하나 이상에서 전부를 포함할 수 있으며, 그 함량은 특별한 제한을 받지 않으며, 비타민 B의 효과는 면역체계 강화, 신경계기능 강화, 췌장암의 발병 위험률 감소, 피부색과 근육 건강을 유지, 신진대사작용을 촉진 등을 들 수 있다.The present invention may include all in any one or more of these vitamin B complexes, and the content is not particularly limited, and the effect of vitamin B is to strengthen the immune system, strengthen the nervous system, reduce the risk of pancreatic cancer, skin color and Maintaining muscle health and promoting metabolism.
상기 비타민 D는 칼슘과 인의 대사에 중요한 역할을 하는 지용성 비타민의 하나. 유기체의 성장, 특히 뼈의 발육과 관련된 칼슘 대사에 필수적이다. 비타민 D는 대부분 태양광선에 의해 만들어지며 음식물로 섭취되는 비타민 D는 많지 않다. 뼈를 튼튼하게 유지하기 위해서는 우리 몸에 충분한 비타민 D가 필요하다.The vitamin D is one of the fat-soluble vitamins that play an important role in the metabolism of calcium and phosphorus. It is essential for the growth of organisms, particularly calcium metabolism, which is involved in the development of bones. Most vitamin D is produced by sunlight, and not much vitamin D comes from food. Your body needs enough vitamin D to keep your bones strong.
상기 산화아연을 투여하는 목적은 아연을 공급하기 위한 것으로 아연은 인체에서는 세포를 구성하는 중요한 물질로, 부족하면 성장 발육에 지장이 발생한다. The purpose of administering the zinc oxide is to supply zinc. Zinc is an important substance constituting cells in the human body, and if it is insufficient, growth and development are disturbed.
상기 식물성 유산균은 김치, 장류, 과일 등 식물성 식품에서 생식하는 유산균을 의미하는 것으로서, 우유, 요구르트 등 동물성 식품에 생식하므로 동물성 유산균과 대비되는 개념이다. 그동안 동물성 유산균의 생존율을 높이기 위해 유산균을 캡슐로 싸는 등 많은 노력을 했지만 큰 효과를 보지 못했으나 식물성 유산균은 원래부터 염분이 많고 산성이 강한 김치, 된장, 간장 등에 서식하는 것이어서 위나 소장의 산성 소화액에서도 잘 죽지 않는 특성을 보인다. 그 종류로는 김치에서 유래한 락토바실러스 플란타럼이나 락토바실러스 루테리, 비피도박테리움 비피덤, 비피도박테리움 브레베 등을 들 수 있다.The plant lactic acid bacteria refers to lactic acid bacteria that reproduce in plant foods such as kimchi, soy sauce, and fruits, and is a concept in contrast to animal lactic acid bacteria because they reproduce in animal foods such as milk and yogurt. In the meantime, many efforts have been made, such as encapsulating lactic acid bacteria in capsules to increase the survival rate of animal lactic acid bacteria, but no great effect has been achieved. It shows the characteristics of not dying easily. Examples thereof include Lactobacillus plantarum, Lactobacillus reuteri, Bifidobacterium bifiderm, and Bifidobacterium breve derived from kimchi.
상기 베리 분말은 아사이베리(Acaiberry), 스트로베리(Strawberry), 크랜베리(Cranberry), 라스베리(Rasberry), 블랙커런트(Blackcurrant), 블랙베리(Blackberry), 블루베리(Blueberry)의 세븐 베리 중에서 하나 이상에서 7가지 전부를 이용하여 제조한 농축 분말을 의미한다.The berry powder is acai berry (Acaiberry), strawberry (Strawberry), cranberry (Cranberry), raspberry (Rasberry), blackcurrant (Blackcurrant), blackberry (Blackberry), blueberry (Blueberry) in at least one of seven berries It means a concentrated powder prepared by using all seven.
상기 베리류는 비타민 C의 함량이 풍부하고, 신맛과 단맛이 잘 조화되어 있어서 대부분 식용으로 이용되고 있으며, 일부 잼. 젤리, 아이스크림, 주류 등의 원료로 이용되고 있다. 베리류는 그 종류에 따라 성분 함량이 다르나 일반적으로 유기산이 많아서 신맛이 많고 당분이 많으며, 비타민C와, 쿼세틴(quercetin), 카페익산(caffeic acid), 페룰릭산(ferulic acid) 등의 폴리페놀물질과 플라보놀(flavonol)류 등의 다양한 항산화 물질이 함유되어 있다. 여기서, 폴리페놀물질은 산화를 방지하는 작용, 즉 항산화 기능을 갖고 있다. 최근 폴리페놀류가 주목 받고 있는 이유는 이 기능이 생체 내에서도 항산화제로 작용함으로써 건강유지와 질병예방 등에 기여할 것으로 기대되기 때문이다. 또한, 폴리페놀류는 콜레스테롤이 소화관으로 흡수되는 것을 막아주기 때문에 혈중 콜레스테롤의 수치를 낮게 해주는 작용도 한다.The berries are rich in vitamin C and have a good balance between sour and sweet, so they are mostly used for food, and some jams. It is used as a raw material for jelly, ice cream, and alcoholic beverages. Berries have different content depending on the type, but generally contain a lot of organic acids, so they have a sour taste and a lot of sugar. It contains various antioxidants such as flavonols. Here, the polyphenol material has an anti-oxidation function, that is, an antioxidant function. The reason why polyphenols have recently been attracting attention is that this function is expected to contribute to health maintenance and disease prevention by acting as an antioxidant in the living body. In addition, polyphenols prevent cholesterol from being absorbed into the digestive tract, thereby lowering the level of cholesterol in the blood.
또한, 베리류의 붉은 색이나 자색의 안토시아닌계 색소 등은 모두 폴리페놀화합물이다. 폴리페놀 물질은 벤젠고리(C6H6)의 수소 중 하나가 수산기(OH)로 치환된 물질을 페놀이라고 하는데, 수산기를 2개 이상 갖고 있는 물질을 폴리페놀, 즉 '다가(多價)페놀'이라고 총칭한다. 이와 같은 구조를 갖는 화합물은 자연계에 주로 존재한다. 베리류는 베리류 특유의 색, 폴리페놀 또는 가장 특별한 안토시아닌과 같은 물질이 항산화, 항염증 및 항암작용을 일으키는데 중요하게 작용하는 것으로 알려져 있다. 특히 베리류 들은 안토시안닌류(anthocyanins)[시아니딘 3-삼부비오사이드(cyanidin 3-sambubioside), 시아니딘 3-글루토사이드(cyanidin 3-glucoside), 시아니딘 3-사이로실루티노사이드(cyanidin 3-xylosylrutinoside), 시아니딘 3-루티노사이드(cyanidin 3-rutinoside)와 펠라고니딘 3-루티노사이드(pelargonidin 3-rutinoside), 플라보노이드류[플라보놀류(flavonols)와 플라바놀류 (flavanols), 탄닌류(tanins)[프로안토시아니딘류(proanthocyanidins), 엘라지탄닌(ellagitannins)과 갈로탄닌(gallotannins)], 스틸베노이드류(stillbenoids) 레스베라트롤(resveratrol) 및 페놀산(phenolic acids) 그리고 리그난류(lignans)가 풍부한 것으로 보고되었다[Boivin D, et al Anticancer Res 27: 937-948 (2007)] 천연물 유래의 페놀 화합물류와 이들의 산화물은 천연물을 이용한 식품이나 음료 등의 색이나 맛 등에 기여하는 구성성분으로 최근에는 항산화, 항돌연변이, 항암 및 항고혈압 효과 등의 각종 생리활성이 밝혀지고 있다.(Cliffe et al, J Agric Food Chem, 42(8), 1824-1828,(1994), Cook and Samman, NutrBiochem,7, 66-76(1996), Bocco et al, J Agric Food Chem, 46(6), 2123-2129(1998))In addition, all of the red and purple anthocyanin-based pigments of berries are polyphenol compounds. As for polyphenol substances, a substance in which one of the hydrogens of the benzene ring (C6H6) is substituted with a hydroxyl group (OH) is called phenol. do. Compounds having such a structure mainly exist in nature. Berries are known to play an important role in producing antioxidant, anti-inflammatory, and anti-cancer properties of berries, such as their unique color, polyphenols, or the most special anthocyanins. In particular, berries contain anthocyanins [cyanidin 3-sambubioside, cyanidin 3-glucoside, and cyanidin 3-xylosylrutinoside. ), cyanidin 3-rutinoside and pelargonidin 3-rutinoside, flavonoids [flavonols and flavanols, tannins] (tanins) [proanthocyanidins, ellagitannins and gallotannins], stillbenoids resveratrol and phenolic acids and lignans [Boivin D, et al Anticancer Res 27: 937-948 (2007)] Phenolic compounds derived from natural products and their oxides are components that contribute to the color and taste of foods or beverages using natural products. Recently, various physiological activities such as antioxidant, antimutagenic, anticancer and antihypertensive effects have been revealed. (Cliffe et al, J Agric Food Chem, 42(8), 1824-1828,(1994), Cook and Samman, NutrBiochem) , 7, 66-76 (1996), Bocco et al, J Agric Food Chem, 46 (6), 2123-2129 (1998))
또한, 베리류에 많이 포함되어 있는 비타민 C는 여러 대사작용에 있어서 필수적인 것으로 알려져 있다. 즉 비타민 C는 콜라겐(피부, 힘줄, 뼈, 지지조직물을 구성하고 상처를 치료해주는 단백질)을 합성, 혈관의 구조강도를 일정하게 유지하고, 특정 아미노산의 대사와 관련이 있으며, 부신 호르몬을 합성 및 유리시킨다. 또한 비타민 C는 질병에 대해 체내의 면역성을 길러준다. 그러나 비타민 C의 각각의 기능에 대한 자세한 정보는 아직도 미흡한 편이다. 비타민 C의 1일 필요량은 성인 남성의 경우 70㎎으로 다른 비타민에 비해 다소 많은 양이며, 감귤류와 신선한 야채에 많이 함유되어 있다. 비타민 C는 중성이나 알칼리 용액 또는 고온에서 산소와 반응하면 쉽게 파괴되기 때문에 보관하기가 어렵다. 비타민 C는 과일이 갈색으로 변하지 않게 하는 데도 쓰인다.In addition, vitamin C, which is abundantly contained in berries, is known to be essential for various metabolic processes. In other words, vitamin C synthesizes collagen (a protein that makes up skin, tendons, bones, supporting tissues and heals wounds), maintains a constant structural strength of blood vessels, is related to the metabolism of specific amino acids, and synthesizes adrenal hormones. and liberate. Vitamin C also boosts the body's immunity to disease. However, detailed information about each function of vitamin C is still lacking. The daily requirement of vitamin C is 70 mg for an adult male, which is somewhat higher than other vitamins, and is contained in citrus fruits and fresh vegetables. Vitamin C is difficult to store because it is easily destroyed when it reacts with oxygen in neutral or alkaline solutions or at high temperatures. Vitamin C is also used to keep fruits from turning brown.
상기 본 발명에서의 분말은 그 자체를 건조하여(열풍 건조, 동결건조) 분쇄한 분말 또는 다양한 추출 용매를 이용하여 추출한 추출물을 농축 건조하여 제조한 분말 모두를 포함하여, 추출 용매로는 정제수 또는 에탄올을 이용하는 것이 바람직하다.The powder in the present invention includes all of the powder prepared by drying itself (hot air drying, freeze-drying) and pulverizing the powder or the extract extracted using various extraction solvents to concentration and drying, as the extraction solvent, purified water or ethanol It is preferable to use
본 발명에 따른 조성물은 알츠하이머 치매, 혈관성 치매 등 퇴행성 뇌병변에 의한 치매를 예방 또는 치료에 도움을 줄 수 있는 다양한 성분들을 포함할 수 있는데, 그 예를 들면 달맞이꽃 오일, 보리지 오일, 알로에베라, 스쿠알렌, 라이코펜, 아보카도 오일, 후코이단, 석곡, 파인베리(백색딸기,뉴클레이클라본이라고도함), 풋사과 폴리페놀 등이 있다.The composition according to the present invention may contain various components that can help prevent or treat dementia caused by degenerative brain lesions such as Alzheimer's dementia and vascular dementia, for example, evening primrose oil, borage oil, aloe vera, There are squalene, lycopene, avocado oil, fucoidan, seokgok, pineberry (also called white strawberry, nucleoclavone), green apple polyphenol, and the like.
상기 달맞이꽃 오일은 달맞이꽃의 씨앗을 압착하여 추출한 식물성 오일로 피부 보습, 재생 효과가 뛰어나고 월경 전 증후군, 월경통, 갱년기 증상 완화에 효과적인이며, 보리지 오일은 보리지의 씨앗을 압착하여 추출한 식물성 오일로 항염, 피부 보습, 재생 효과가 뛰어나고 월경 전 증후군, 갱년기 증상 완화에 도움을 준다.The evening primrose oil is a vegetable oil extracted by pressing the seeds of evening primrose. It has excellent skin moisturizing and regeneration effects and is effective in relieving premenstrual syndrome, menstrual pain, and menopausal symptoms. It has excellent skin moisturizing and regenerative effects, and helps to relieve premenstrual syndrome and menopausal symptoms.
상기 알로에베라는 아프리카가 원산지인 백합과의 다년초. 지중해 지방과 아프리카가 원산지로, 잎을 자르면 나오는 맑은 젤 형태의 수액은 화상과 관절염을 치료하는 효과가 있으며, 탄소 30개, 수소 50개가 여섯 개의 이중 결합으로 연결된 triterpenoid계의 불포화 탄화수소로 인체와 동식물성 유지에 함유되어 있다. 심해상어 간유(肝油)에 특히 많이 함유되어 있으며 올리브오일, 야자유, 밀배아유 등에도 함유되어 있고, 인체 내에서는 아세틸보조효소 A로부터 메발론산을 거쳐 합성되며, 콜레스테롤, 생식 호르몬, 비타민 D, 담즙산 생산 등에 사용되는 것으로 알려져 있다.The aloe vera is a perennial plant of the lily family that is native to Africa. Native to the Mediterranean region and Africa, the clear gel-type sap that comes out when the leaves are cut is effective in treating burns and arthritis. It is contained in vegetable oils. It is particularly abundant in deep-sea shark liver oil, and it is also contained in olive oil, palm oil, wheat germ oil, etc. In the human body, it is synthesized from acetyl coenzyme A through mevalonic acid, cholesterol, reproductive hormones, vitamin D, and bile acids. It is known to be used in production.
상기 라이코펜은 피토케미칼(phytochemical)로서 토마토와 같은 붉은색을 가진 과일(토마토, 수박, 감, 붉은 포도, 석류, 자몽, 구아바)에 풍부하게 들어 있다. 베타카로틴과 같이 체내에서 비타민 A로 전화되는 것은 아니지만 베타카로틴 이상의 강력한 항산화작용을 하며, 노화방지, 항암효과(전립선암), 심혈관질환 예방 및 혈당저하 효과를 나타낸다. 특히 암세포 성장을 도모하는 주요 조절 인자인IGF-1(insulin like growth factors) 인자를 강력하게 억제하며, 단백질 43효소를 자극하여 세포 간 연락장치를 발현시키는데, 세포 간 연락장치의 발현은 암의 억제와 깊은 연관이 있다.The lycopene is a phytochemical and is abundantly contained in fruits having a red color such as tomatoes (tomatoes, watermelons, persimmons, red grapes, pomegranates, grapefruit, and guava). Although it is not converted into vitamin A in the body like beta-carotene, it has a stronger antioxidant action than beta-carotene, and has anti-aging, anti-cancer effects (prostate cancer), cardiovascular disease prevention and blood sugar lowering effects. In particular, it strongly inhibits IGF-1 (insulin like growth factors) factor, a major regulatory factor that promotes cancer cell growth, and stimulates protein 43 enzyme to express the intercellular communication device, and the expression of the intercellular communication device suppresses cancer is closely related to
상기 아보카도 오일은 단일 불포화지방산 함량이 매우 높아 건강 식품으로 알려져 있다. 연소점이 아주 높아서 까마득한 고온의 열에서도 조리가 가능하므로 요리에도 엄청나게 쓸모가 많다. 걸쭉하고 벨벳처럼 부드러운 질감에 종종 환상적인 짙은 녹색의 빛깔이 어우러진, 가장 매력적인 식용유 가운데 하나이다. The avocado oil has a very high monounsaturated fatty acid content and is known as a health food. It has a very high combustion point, so it can be cooked even at very high temperatures, so it is extremely useful for cooking. It is one of the most attractive cooking oils, with its thick, velvety-soft texture and often a fantastic dark green hue.
상기 후코이단은 갈조류에 유연성을 부여하여 격렬한 조수의 흐름으로부터 해조류가 보호될 수 있도록 한다. 갈조류로부터 추출된 후코이단은 평균 분자량 20kDa이며, 후코스(Fucose)라는 기본당과 황산기가 결합되어 있다. 황산화후코이단에서 생기는 F-후코이단과 20% 정도의 글루쿠론산를 포함한 U-후코이단 두 종류가 있다. 기능성 식품의 기초원료, 식이보조제, 첨가제 등으로 사용되고 있는 것으로 알려지고 있다. 후코이단은 콜레스테롤의 배설을 도와 혈중 콜레스테롤 수치를 낮추며 혈관 질환을 예방할 수 있고 비만이 성인병으로 발병되는 것을 예방시켜 준다.The fucoidan gives flexibility to brown algae so that the algae can be protected from the violent tidal flow. Fucoidan extracted from brown algae has an average molecular weight of 20 kDa, and a basic sugar called fucose and a sulfate group are combined. There are two types: F-fucoidan, which is generated from sulfated fucoidan, and U-fucoidan, which contains about 20% glucuronic acid. It is known to be used as a basic raw material for functional foods, dietary supplements, and additives. Fucoidan helps excretion of cholesterol, lowers blood cholesterol levels, prevents vascular diseases, and prevents obesity from developing into adult diseases.
상기 석곡은 난과의 금채석곡(Dendrobium nobile Lindley:金釵石斛) 또는 동속 근연식물의 지상부로 만든 약재로 진액을 보충하고 열을 내리며 위음을 자양해주므로 외감성으로 인한 진액손상, 인후건조, 가슴답답증, 갈증에 쓰고 입 안이 마르고 대변이 굳는 증상, 간음부족으로 인한 시력감퇴, 요통 등에 사용한다. The above-mentioned Seokgok is a medicinal material made from the above-ground part of Dendrobium nobile Lindley (金釵石斛) of the orchid family or a closely related plant to replenish the essence, lower the heat, and nourish the stomach. , used for thirst, dry mouth, hard stool, loss of vision due to lack of adultery, and back pain.
상기 파인베리는 흰색 또는 연분홍색 과육에 붉은색 씨앗을 가진 딸기이다. ‘파인애플 딸기(ananaserdbeere)’라고도 불리며, 붉은색의 일반 딸기보다 크기는 작지만 당도가 높고 파인애플과 유사한 향이 난다. 또한 상기 풋사과 폴리페놀은 활성산소에 노출되어 손상되는 DNA의 보호나 세포구성 단백질 및 효소를 보호하는 항산화 능력이 커서 다양한 질병에 대한 위험도를 낮춘다고 보고되고 있다. 또한 폴리페놀은 항암작용과 함께 심장질환을 막아주는 것으로 알려져있다. The pineberry is a strawberry with red seeds in white or light pink flesh. Also called ‘pineapple strawberry (ananaserdbeere)’, it is smaller in size than normal red strawberries, but has a high sugar content and a scent similar to pineapple. In addition, it is reported that the green apple polyphenol has a high antioxidant ability to protect DNA or cellular proteins and enzymes damaged by exposure to free radicals, thereby lowering the risk of various diseases. In addition, polyphenols are known to have anti-cancer properties and prevent heart disease.
본 발명의 조성물은 허용 가능한 담체를 포함할 수 있다.The compositions of the present invention may include an acceptable carrier.
본 발명에서 용어 "허용 가능한 담체"는 생물체를 자극하지 않으면서, 주입되는 화합물의 생물학적활성 및 특성을 저해하지 않는 담체, 부형제 또는 희석제를 의미할 수 있으며, 구체적으로, 비자연적 담체(nonnaturally occuring carrier)일 수 있다. 본 발명에 사용 가능한 상기 담체의 종류는 특별히 제한되지 아니하며 당해 기술 분야에서 통상적으로 사용되고 약학적으로 허용되는 담체라면 어느 것이든 사용할 수 있다. In the present invention, the term "acceptable carrier" may mean a carrier, excipient or diluent that does not inhibit the biological activity and properties of the injected compound without stimulating the organism, and specifically, a non-naturally occurring carrier (non-naturally occurring carrier) ) can be The type of carrier usable in the present invention is not particularly limited, and any carrier commonly used in the art and pharmaceutically acceptable may be used.
상기 조성물은 유효한 양으로 투여할 수 있다. 상기 "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 개체 종류 및 중증도, 연령, 성별, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료 기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. The composition may be administered in an effective amount. The "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level depends on the subject type and severity, age, sex, activity of the drug, and the drug. Sensitivity to, administration time, administration route and excretion rate, duration of treatment, factors including concomitant drugs, and other factors well known in the medical field.
또한, 본 발명에서 용어 "식품"은 육류, 소시지, 빵, 초콜릿, 캔디류, 스텍류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올음료, 비타민 복합제, 건강 기능 식품 및 건강 식품 등이 있으며, 통상적인 의미의 식품을 모두 포함한다.In the present invention, the term "food" refers to meat, sausage, bread, chocolate, candy, stacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, tea, drinks, There are alcoholic beverages, vitamin complexes, health functional foods, and health foods, and includes all foods in the ordinary sense.
상기 건강기능(성) 식품(functional food)이란, 특정보건용 식품(food for special health use, FoSHU)와 동일한 용어로, 영양 공급 외에도 생체조절기능이 효율적으로 나타나도록 가공된 의학, 의료효과가 높은 식품을 의미한다. 여기서 "기능(성)"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미한다. 본 발명의 식품은 당 업계에서 통상적으로 사용되는 방법에 의하여 제조 가능하며, 상기 제조시에는 당 업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. The functional food is the same term as food for special health use, FoSHU. means food. Here, "function (sex)" means to obtain a useful effect for health purposes such as regulating nutrients or physiological action with respect to the structure and function of the human body. The food of the present invention can be prepared by a method commonly used in the art, and at the time of manufacture, it can be prepared by adding raw materials and components commonly added in the art.
또한. 상기 식품의 제형 또한 식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 발명의 식품용 조성물은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 본 발명의 식품은 알츠하이머 완화를 위한 보조제로 섭취가 가능하다.In addition. The formulation of the food may also be prepared without limitation as long as it is a formulation recognized as a food. The composition for food of the present invention can be prepared in various forms, and unlike general drugs, it has the advantage that there are no side effects that may occur when taking the drug for a long period of time using food as a raw material, and has excellent portability, and the present invention Foods of can be taken as a supplement to alleviate Alzheimer's.
이하, 본 발명을 실시예를 통하여 더욱 상세히 설명한다. 그러나 하기 실시예는 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이에 제한되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. However, the following examples are intended to illustrate the present invention, and the scope of the present invention is not limited thereto.
<< 실시예Example 1: 항 알츠하이머 효과 시험> 1: Anti-Alzheimer's Effect Test>
1. 동물의 준비1. Preparation of Animals
모든 동물은 시험용 동물에 대한 복지 및 이용을 위한 NIH 가이드(NIH Publication No 85-23, 1985; wwwdelsnasedu/ila)를 준수하여 처리하였다. 본 발명은 시험용 동물에 대한 복지 및 이용을 위한 ILAR(Institute for Laboratory Animal Research) 가이드라인에 따라 수행되었다. All animals were treated in accordance with the NIH Guide for the Welfare and Use of Test Animals (NIH Publication No 85-23, 1985; wwwdelsnasedu/ila). The present invention was carried out in accordance with ILAR (Institute for Laboratory Animal Research) guidelines for the welfare and use of test animals.
알츠하이머 모델 동물로서 6월령의 APP/PS1(amyloid precursor protein / presenilin-1, APPswe/PS1dE9) 이중 발현(double transgenic) 마우스(The Jackson Laboratory, Bar Harbor, MA, USA)를 사용하였으며, 12:12h 명:암 사이클을 유지하며 자유식(ad libitum)시켰다.6-month-old APP/PS1 (amyloid precursor protein/presenilin-1, APPswe/PS1dE9) double transgenic mice (The Jackson Laboratory, Bar Harbor, MA, USA) were used as Alzheimer's model animals, 12:12h : The arm cycle was maintained and ad libitum was carried out.
2. 조성물 처리2. Composition treatment
하기 처리 조성물을 각각 50mg/kg을 시험 동물에 90일 동안 투여하였고, 60일 ∼ 63일 및 90일 ∼ 93일에 행동 평가(Y-미로시험, 신물체인식시험, 수동회피시험)을 수행하였다.Each of the following treatment compositions was administered at 50 mg/kg to test animals for 90 days, and behavioral evaluation (Y-maze test, body recognition test, passive avoidance test) was performed on
시험은 조성물 1 처리군, 조성물 2 처리군, 조성물 3 처리군 및 대조군(No treatment)의 4개 군으로 분류하여 진행하였고, 각 군은 n=6이었다.The test was carried out by classifying it into 4 groups:
처리 조성물 1: 굼벵이 분말로 이루어진 조성물Treatment composition 1: composition consisting of slug powder
처리 조성물 2: 굼벵이 분말과 치커리 뿌리 추출 분말로 이루어진 중량비율 1:1의 조성물Treatment composition 2: A composition in a weight ratio of 1:1 consisting of slug powder and chicory root extract powder
처리 조성물 3: 굼벵이 분말, 비타민 B1 (티아민), 비타민 B2 (리보플래빈), 비타민 B3 (나이아신, 니코틴아마이드), 비타민 B5 (판토텐산), 비타민 B6 (피리독신, 피리독살, 피리독사민), 비타민 B7 (바이오틴), 비타민 B9 (폴산, 엽산). 비타민 B12 (코발라민), 산화아연; 식물성 유산균으로 락토바실러스 플란타럼, 치커리 뿌리 추출물, 비타민 C, 비타민 D, 돼지 태반 추출물, 아사이베리(Acaiberry), 스트로베리(Strawberry), 크랜베리(Cranberry), 라스베리(Rasberry), 블랙커런트(Blackcurrant), 블랙베리(Blackberry) 및 블루베리(Blueberry)로 이루어진 중량비율 굼벵이 분말 20; 치커리 뿌리 추출 분말 20; 나머지 각각 0.1의 조성물Treatment composition 3: slug powder, vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B3 (niacin, nicotinamide), vitamin B5 (pantothenic acid), vitamin B6 (pyridoxine, pyridoxal, pyridoxamine), vitamin B7 (biotin), vitamin B9 (folic acid, folic acid). vitamin B12 (cobalamin), zinc oxide; Plant Lactobacillus Plantarum, Chicory Root Extract, Vitamin C, Vitamin D, Pig Placenta Extract, Acaiberry, Strawberry, Cranberry, Raspberry, Blackcurrant , blackberry (Blackberry) and blueberry (Blueberry), weight
상기 굼벵이 분말로는 물에 잘 세척, 건조된 굼뱅를 넣고 발효균주로서 Bacillus subtilis var. natto를 건조 굼뱅이 중량 대비 3중량% 정도 양을 첨가하여 상온에서 유지하면서 20시간 동안 발효를 진행하여 상층부의 유상과 하층부의 수상을 분리한 후에 분리된 수상을 1㎛ 필터를 이용하여 감압 여과한 다음 여과된 수상을 121℃, 30분간 멸균하여 미생물을 제거하고 이 용액을 동결건조한 수용성 굼뱅이 펩타이드 분말을 제조하여 사용하였다.As the slug powder, washed well in water and dried slugs were added, and as a fermentation strain, Bacillus subtilis var. After adding natto in an amount of about 3% by weight based on the weight of the dried slugs and maintaining it at room temperature, fermentation was carried out for 20 hours to separate the oil phase of the upper layer and the aqueous phase of the lower layer, and then the separated aqueous phase was filtered under reduced pressure using a 1㎛ filter. The filtered aqueous phase was sterilized at 121° C. for 30 minutes to remove microorganisms, and the solution was freeze-dried to prepare and use a water-soluble slug peptide powder.
3. 3. 항알츠하이머anti-alzheimer's 효능 평가 Efficacy evaluation
(1) Y-미로 시험(Y-maze)(1) Y-maze test (Y-maze)
Y-자형 미로 시험은 선행문헌[J Alzheimers Dis(31, 207-223)]에 기재된 바에 따라 수행하였다. Y-maze의 구성은 Y-자 형태의 arm으로 되어 있고 길이 25cm X 25cm X 14cm의 검은 플라스틱 상자로 되어 있다.The Y-shaped maze test was performed as described in J Alzheimers Dis (31, 207-223). The Y-maze consists of a Y-shaped arm and a black plastic box with a length of 25cm X 25cm X 14cm.
마우스를 한쪽 팔의 끝에 놓고 8분 동안 암 사이를 자유롭게 왕래하도록 한다. 마우스가 각각의 암에 들어가는 횟수를 비디오카메라로 찍는다. 공간 교체행동(Alternation behavior)의 평가 지표는 3개의 암을 모두 들어가는 경우에 1점을 획득하는 것으로 하여 대조군과 비교했다. 마우스의 교체 스코어는 실제 마우스가 획득한 스코어를 가능한 교체 스코어로 나누어 100%로 환산한다.Place the mouse on the tip of one arm and allow it to move freely between arms for 8 min. The number of times the mouse enters each arm is recorded with a video camera. The evaluation index of the alternative behavior (Alternation behavior) was compared with the control group by obtaining 1 point in the case of entering all three cancers. The replacement score of the mouse is converted to 100% by dividing the score obtained by the actual mouse by the possible replacement score.
(2) (2) 신물체new body 인식시험(Novel Object Recognition) Novel Object Recognition
신물체 인식시험은 선행문헌[Learn Mem(14, 117-125)]에 기재된 바에 따라 수행하였다. 첫날에는 마우스를 40cm X 40cm X 30cm의 상자에 넣고 10분간 자유롭게 이동하도록 하여 적응시킨다. 2일째에는 상자에 두 개의 물체를 놓고 각각의 물체에 대한 반응시간을 기록한다. 이로부터 24시간 후 두 개 중 한 개의 물체를 새로운 물체(novel object)로 바꾼 후 이에 대한 반응시간을 기록한다.The new body recognition test was performed as described in the prior literature [Learn Mem (14, 117-125)]. On the first day, acclimatize the mice by placing them in a box of 40
(3) 수동회피시험(Passive Avoidance test)(3) Passive Avoidance test
수동회피시험은 선행문헌[Behav Brain Res(155, 185-196)]에 기재된 바에 따라 Gemini Avoidance System(SanDiego Instrument, San Diego, CA)를 이용하여 수행하였다. 상기 시스템은 바닥에 쇼크발생기가 장치되어진 2개의 공간으로 이루어져 있으며 두 공간의 사이에는 기요틴 도어(guillotine door)가 있다. The passive avoidance test was performed using the Gemini Avoidance System (SanDiego Instrument, San Diego, CA) as described in the prior literature [Behav Brain Res (155, 185-196)]. The system consists of two spaces in which a shock generator is installed on the floor, and there is a guillotine door between the two spaces.
학습단계(Acquisition trial)에서는 마우스를 한 공간(start chamber)에 넣은 후 20초간 적응시키고, 20초 후 마우스가 넣어진 공간에 불이 켜지면서 가운데의 기요틴 도어(guillotine door)가 열리게 된다. 마우스가 불이 켜지지 않은 반대편 공간으로 들어가는 즉시 기요틴 도어(guillotine door)가 닫히면서 전기 쇼크(03 mA, 3s, 1회)가 주어지게 된다.In the learning phase (Acquisition trial), the mouse is put in a start chamber and then acclimatized for 20 seconds, and after 20 seconds, the light in the space in which the mouse is put is turned on and the guillotine door in the middle is opened. As soon as the mouse enters the opposite space where the light is not turned on, the guillotine door closes and an electric shock (03 mA, 3s, 1 time) is given.
24시간 후 보류 시험(retention trial)에서는 마우스를 시작 챔버(start chamber)에 다시 넣고 불을 켠 후, 반대쪽 공간으로 가는 시간(step-through latency)를 기록한다(최고 300초).In a retention trial after 24 hours, the mice were placed back in the start chamber, turned on, and the step-through latency was recorded (up to 300 seconds).
(4) 콜린 (4) Choline 아세틸트랜스퍼라제acetyltransferase 활성( activation( ChATChAT activity), 아세틸콜린 수준( activity), acetylcholine levels ( AchAch level) 및 아세틸콜린 분해효소 활성( level) and acetylcholinease activity ( AchEAchE activity) 측정 activity) measurement
마우스는 수동 회피시험이 끝난 24시간 뒤, 해마 및 피질 부위를 절취하여 초음파 조직분쇄기(Bronson Sonic, NY)로 분쇄한 후 10,000g, 4℃ 에서 20분간 원심분리 후 상층액을 취하여 아세틸콜린(acetylcholine) 농도, 아세틸콜린 분해효소(acetyl cholinesterase), 콜린 아세틸트랜스퍼라제(choline acetyltransferase)의 활성을 측정하였다.24 hours after the manual avoidance test, the hippocampus and cortex were cut out, crushed with an ultrasonic tissue grinder (Bronson Sonic, NY), centrifuged at 10,000 g, 4 ° C for 20 minutes, and the supernatant was taken and acetylcholine (acetylcholine) was removed. ) concentration, acetyl cholinesterase, and choline acetyltransferase activity were measured.
해마와 피질 조직의 ACh 수치 및 AChE의 활성은 키트(Amplex® Red Acetylcholine/ Acetylcholinesterase Assay Kit, Molecular Probes, Inc, Eugene, KOR)를 이용하여 제작회사의 프로토콜에 따라 측정하였다.ACh levels and AChE activity in hippocampal and cortical tissues were measured using a kit (Amplex® Red Acetylcholine/ Acetylcholinesterase Assay Kit, Molecular Probes, Inc, Eugene, KOR) according to the manufacturer's protocol.
ChAT의 활성은 Mehta 등의 방법[Mehta H, Haobam R, Usha R, Mohanakumar KP Evidence for the involvement of central serotonergic mechanism in cholinergic tremor induced by tacrine in Balb/c mice Behav Brain Res 20.05; 163: 227-236]에 따라 측정하였다. 즉, 0.5M 소듐 포스페이트 완충액(sodium phosphate buffer, pH 7.2), 아세틸-CoA(acetyl-CoA, 6.2mM), 콜린 클로라이드(choline chloride, 1M), 네오스티그민 설페이트(neostigmine sulfate, 0.76mM), NaCl(3M), EDTA(11mM)의 용액을 각각 25㎕씩 취한 후 증류수를 이용하여 부피를 400㎕ 맞추었다. 이 용액을 37℃에서 5분간 미리 인큐베이션(preincubation)한 후, 시료 100㎕을 넣어 37℃에서 20분간 인큐베이션(incubation)하였다.ChAT activity was determined by Mehta et al. [Mehta H, Haobam R, Usha R, Mohanakumar KP Evidence for the involvement of central serotonergic mechanism in cholinergic tremor induced by tacrine in Balb/c mice Behav Brain Res 20.05; 163: 227-236]. Namely, 0.5M sodium phosphate buffer (pH 7.2), acetyl-CoA (6.2 mM), choline chloride (1M), neostigmine sulfate (0.76 mM), NaCl (3M) and 25 μl of EDTA (11 mM) solutions were each taken, and the volume was adjusted to 400 μl using distilled water. This solution was preincubated at 37°C for 5 minutes, and then 100 μl of the sample was added and incubated at 37°C for 20 minutes.
검체를 2분간 끓여서 반응을 종결시킨 후, 1ml의 증류수를 넣고, 원심분리하여 변성된 단백질(denatured protein)을 제거한 후 1ml의 상등액을 디티오피리딘(4,4′-dithiopyridine, 10mM)이 30㎕ 들어 있는 시험관에 넣고, 15분 후 324nm에서 흡광도를 측정하였다.After boiling the sample for 2 minutes to terminate the reaction, 1 ml of distilled water was added, centrifuged to remove denatured protein, and 1 ml of the supernatant was diluted with 30 μl of dithiopyridine (4,4′-dithiopyridine, 10 mM). It was placed in a test tube and the absorbance was measured at 324 nm after 15 minutes.
ChAT의 활성은 조효소(coenzyme) nmol/hr·g protein으로 표기하였다. 단백질 농도는 BCA 단백질 에세이 시약(protein assay reagent, Pierce, Rockford, IL, USA)를 이용하여 제작회사의 프로토콜에 따라 측정하였다.ChAT activity was expressed as coenzyme nmol/hr·g protein. Protein concentration was measured using a BCA protein assay reagent (Pierce, Rockford, IL, USA) according to the manufacturer's protocol.
4. 시험 결과4. Test results
(1) Y-자형 미로시험(Y-maze test)(1) Y-maze test
시험 결과를 도 3에 나타냈으며, 도 3을 보면 마우스에서 본 발명의 조성물 투여는 대조군에 비하여 공간교체행동을 유의하게 증가시켰다(50mg/kg, P<0.05). The test results are shown in FIG. 3 . Referring to FIG. 3 , administration of the composition of the present invention in mice significantly increased the space change behavior compared to the control group (50 mg/kg, P<0.05).
본 발명의 조성물은 투여 기간을 늘릴수록 증가 경향은 더욱 현저하였으며, 특히 조성물 2 및 3에서 조성물 1 보다 더 우수한 효과를 나타냈다. The composition of the present invention showed a more remarkable increase trend as the administration period was increased, and in particular,
(2) (2) 신물체new body 인식시험 cognitive test
시험 결과를 도 4에 나타냈으며, 도 4를 보면 마우스에서 본 발명의 조성물의 투여는 대조군에 비하여 새로운 물체 인식 시험에서 새로운 물체에 대한 탐색행위를 유의하게 증가시켰으며(P<0.05), 이는 시각 재인지 기억력(visual recognition memory)의 증가를 의미한다.The test results are shown in FIG. 4 , which shows that administration of the composition of the present invention in mice significantly increased the search behavior for new objects in the new object recognition test compared to the control group (P<0.05), which It means an increase in visual recognition memory.
본 발명의 조성물은 투여 기간을 늘릴수록 증가 경향은 더욱 현저하였으며, 특히 조성물 2 및 3에서 조성물 1 보다 더 우수한 효과를 나타냈다. The composition of the present invention showed a more remarkable increase trend as the administration period was increased, and in particular,
(3) 수동회피시험(3) Passive evasion test
시험 결과를 도 5에 나타냈으며, 도 5를 보면 마우스에서 본 발명의 조성물의 투여는 대조군에 비하여 수동회피반응시험에서 검은 방으로 가는 stepthrough latency를 유의하게 증가시켰으며(P<0.05), 이는 연합학습능력(associative learning)의 증가를 의미한다. The test results are shown in FIG. 5, and the administration of the composition of the present invention in mice significantly increased the stepthrough latency to the black room in the passive avoidance test compared to the control group (P<0.05), which was associated with It means an increase in associative learning.
본 발명의 조성물은 투여 기간을 늘릴수록 증가 경향은 더욱 현저하였으며, 특히 조성물 2 및 3에서 조성물 1 보다 더 우수한 효과를 나타냈다. The composition of the present invention showed a more remarkable increase trend as the administration period was increased, and in particular,
(4) 콜린 (4) Choline 아세틸트랜스퍼라제acetyltransferase 활성, 아세틸콜린 수준 및 아세틸콜린 분해효소 활성 측정 Determination of activity, acetylcholine levels and acetylcholinease activity
시험 결과를 도 6 내지 8에 나타냈으며, 도 6 내지 8을 보면 마우스에서 본 발명의 조성물의 투여는 대조군에 비하여 해마(hippocampus) 조직의 아세틸콜린 농도(P<0.05)와 아세틸콜린 합성효소인 콜린아세틸트렌스페라제의 활성을 유의하게 증가시켰고(P<0.05), 아세틸콜린분해효소인 아세틸콜린에스터라제의 활성은 유의하게 감소시켰으며(P<0.05), 이는 해마의 콜린성 신경계 기능이 증가되었음을 의미한다.The test results are shown in Figs. 6 to 8, and the administration of the composition of the present invention in mice was compared to the control group at the concentration of acetylcholine in the hippocampus tissue (P<0.05) and the acetylcholine synthetase choline. The activity of acetyltransferase was significantly increased (P<0.05), and the activity of acetylcholinesterase, an acetylcholinesterase, was significantly decreased (P<0.05), indicating that the cholinergic nervous system function of the hippocampus was increased. it means.
상기 결과는 본 발명의 조성물의 투여가 해마의 콜린성 신경계 기능 향상에 유의한 약리 효능이 있음을 나타내며, 특히 조성물 2 및 3에서 조성물 1 보다 더 우수한 효과를 나타냈다. The above results indicate that administration of the composition of the present invention has a significant pharmacological effect on improving hippocampal cholinergic nervous system function, and in particular,
<< 실시예Example 2: 2: 뇌허혈(cerebral ischemia)에in cerebral ischemia 의해 유발되는 뇌손상 조직의 보호 효과> Protective effect of brain damaged tissue caused by
뇌허혈에 의해 유발된 뇌조직 손상(infarction)에 대한 영지 추출물의 보호효과를 관찰하기 위하여 쥐의 중관상동맥을 폐쇄(middle coronary artery occlusion; MCAO)하여 뇌허혈 동물모델을 만들었다(Longa et al, 1986)To observe the protective effect of Ganoderma extract against brain tissue infarction induced by cerebral ischemia, an animal model of cerebral ischemia was created by occluding middle coronary artery occlusion (MCAO) in mice (Longa et al, 1986).
체중 250~300g의 웅성 흰쥐(Sprague-Dawley)를 사용하였으며, 뇌허혈 유발 전후 물과 먹이는 자유롭게 섭취하도록 하였으며, 약 1주일간의 순응기간을 거친 후 시험에 사용하였다.Male rats (Sprague-Dawley) weighing 250-300 g were used, and they were allowed to freely drink water and food before and after induction of cerebral ischemia.
마취 챔버에서 30~35%의 엔플로란(enflurane, 중외제약)을 도입하여 마취 유도 후 수술대에 고정시키고, 다시 마스크로 15~20%의 엔플로란을 도입하여 수술 중 마취가 지속되도록 하였다. 체온저하를 막기 위해 수술시 전기담요(heating pad)를 이용하여 체온을 37±0.5℃로 유지하였다. 목의 중앙선을 따라 경부를 1cm 정도 절개한 후 오른쪽 총경동맥(common carotid artery)을 조심스럽게 미주신경(vagus nerve)과 분리시켜 노출시켰다. 총경동맥으로부터 외경동맥(external carotid artery)과 내경동맥(internal carotid artery)을 주변의 신경으로부터 분리해내고 박리한 총경동맥, 외경동맥 및 내경동맥에 미리 실을 느슨하게 걸어 놓았다. 총경동맥 및 외경동맥에 건 실을 묶어 총경동맥 및 외경동맥을 결찰하고 내경동맥 기시부에 주사침으로 구멍을 낸 다음 절개부위를 통해 내경동맥 쪽으로 17mm 길이의 프로브(probe)를 밀어 넣어 중대뇌동맥을 폐쇄하고, 내경동맥에 걸어 둔 실을 묶어 프로브를 고정하여 허혈을 유발시켰다. 이 때 프로브는 나일론 수술용 실(nylon surgical thread)의 한쪽 끝을 인두 가까이에서 열을 가해 그 끝의 직경이 03mm가 되도록 하여 마개(stopper)로 사용하고, 길이가 17mm 정도 되도록 자른 다음 경화제(Optosil, Bayer Dental)를 첨가한 실리콘(Xantopren, Bayer Dental)으로 코팅한 것을 사용하였다. 수술부위를 봉합하고 마취에서 깨어날 때까지 다른 케이지(cage)에 두었다. 뇌허혈 유발 후 일정시간(약 30분)이 경과했을 때 신경학적 결손을 확인하였다. 신경학적 결손은 공중에서 흰 쥐의 꼬리를 완전히 들었을 때 좌측부 전마비(left hemiparesis)가 일어나는지와 꼬리를 위로 들었을 때 또는 자발적으로 왼쪽으로의 회선병(circling)이 일어나는지 관찰하였다(Bederson et al, 1986) After induction of anesthesia by introducing 30~35% of enflurane (Chungwae Pharmaceutical) in the anesthesia chamber, 15~20% of enflurane was introduced as a mask to continue anesthesia during surgery. In order to prevent body temperature drop, the body temperature was maintained at 37±0.5° C. using an electric blanket during surgery. After making a 1 cm incision in the neck along the midline of the neck, the right common carotid artery was carefully separated from the vagus nerve and exposed. The external carotid artery and the internal carotid artery were separated from the surrounding nerves from the common carotid artery, and a thread was previously loosely hung on the dissected common carotid artery, external carotid artery, and internal carotid artery. The common carotid artery and the external carotid artery are ligated by tying a tendon thread to the common carotid artery and the external carotid artery, a hole is made at the origin of the internal carotid artery with a needle, and a 17mm-long probe is pushed through the incision toward the internal carotid artery to close the middle cerebral artery. , ischemia was induced by fixing the probe by tying a thread hung on the internal carotid artery. At this time, the probe is used as a stopper by heating one end of a nylon surgical thread near the pharynx so that the diameter of the tip becomes 03mm, cutting it to about 17mm in length, and then using a hardener (Optosil). , Bayer Dental) added silicone (Xantopren, Bayer Dental) was used. The surgical site was sutured and placed in another cage until awakening from anesthesia. When a certain period of time (about 30 minutes) has elapsed after inducing cerebral ischemia, a neurological deficit was confirmed. Neurological deficits were observed in white rats with left hemiparesis when the tail was fully lifted in the air, and circling to the left when the tail was lifted up or spontaneously (Bederson et al, 1986). )
본 시험에서는 조성물 2(0.5㎎/㎏, 2.0㎎/㎏, 10㎎/㎏)를 복강 내 전투여(pre-treatment)한 후 30분 후에 중대뇌동맥을 폐쇄시켜 9시간 동안 뇌허혈을 유발시킨후 단두하여 신속하게 뇌를 적출하였다. Brain matrix(Neurotec 한국)를 이용하여 전두극(frontal pole)으로부터 1㎜ 되는 지점부터 2㎜ 두께의 연속적으로 구분되어진 신선한 뇌관측 조각(fresh brain coronal slice) 중 세번째 조각(5~7㎜)에 0.9% 생리식염수로 제조된 2% TTC(2,3,5-triphenyltetrazolium chloride) 용액을 가하고 37℃에서 30분간 염색하여 뇌손상 정도를 측정하여 그 결과를 도 9에 나타냈다.In this test, after intraperitoneal pre-treatment with Composition 2 (0.5 mg/kg, 2.0 mg/kg, 10 mg/kg), the middle cerebral artery was occluded 30 minutes later to induce cerebral ischemia for 9 hours, and then the single head The brain was quickly removed. Using a brain matrix (Neurotec Korea), 0.9 in the third piece (5-7 mm) of fresh brain coronal slices continuously separated 2 mm thick from the
도 9에서 보는 바와 같이, 9시간 허혈로 인해 유도된 대뇌피질과 선조체에서의 손상범위(희게 보이는 부위)가 본 발명에 따른 조성물 2 투여에 의해 감소됨을 알 수 있다.As shown in FIG. 9 , it can be seen that the range of damage (the area that appears white) in the cerebral cortex and the striatum induced by ischemia for 9 hours is reduced by administration of the
Claims (7)
A functional food composition for preventing or alleviating symptoms of dementia comprising, as an active ingredient, any one or more selected from the group consisting of slug dry powder, slug blood lymph, and slug fermented broth.
The functional for prevention or symptom relief of dementia according to claim 1, wherein the slug blood lymph is a supernatant obtained by puncturing slugs with a needle or freezing and thawing slugs, then installing them in a centrifuge and centrifuging them. food composition.
The method according to claim 1 or 2, wherein the slug fermentation broth is prepared by adding slugs or pulverized slugs to water, and Bacillus subtilis var. A functional food composition for preventing or alleviating symptoms of dementia, characterized in that it is fermented by inoculating any one or more strains selected from the group consisting of natto strains, Bacillus subtilis strains and Aspergillus kawachii strains.
The functional food composition for preventing or alleviating symptoms of dementia according to claim 1, further comprising chicory root extract.
비타민 B1, 비타민 B2, 비타민 B3, 비타민 B5, 비타민 B6, 비타민 B7, 비타민 B9 및 비타민 B12로 이루어진 군에서 선택되는 어느 하나 이상의 비타민 B;
비타민 C;
비타민 D;
산화아연;
식물성 유산균;
치커리 뿌리 추출물;
돼지 태반 추출물; 및
아사이베리(Acaiberry), 스트로베리(Strawberry), 크랜베리(Cranberry), 라스베리(Rasberry), 블랙커런트(Blackcurrant), 블랙베리(Blackberry) 및 블루베리(Blueberry)로 이루어진 군에서 선택되는 어느 하나의 베리;를
더 포함하는 것을 특징으로 하는 치매의 예방 또는 증상 완화용 기능성 식품 조성물.
The method of claim 1,
any one or more B vitamins selected from the group consisting of vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B9, and vitamin B12;
vitamin C;
vitamin D;
zinc oxide;
plant lactic acid bacteria;
chicory root extract;
pig placenta extract; and
Acai berry (Acaiberry), strawberry (Strawberry), cranberry (Cranberry), raspberry (Rasberry), blackcurrant (Blackcurrant), blackberry (Blackberry) and any one berry selected from the group consisting of blueberry (Blueberry); cast
Functional food composition for preventing or alleviating symptoms of dementia, characterized in that it further comprises.
Section 1. The method according to any one of claims 4 and 5, wherein evening primrose oil, borage oil, aloe vera, squalene, lycopene, avocado oil, fucoidan, seokgok, pineberry (also called white strawberry, nucleoclavone) and green apple Functional food composition for preventing or alleviating symptoms of dementia, characterized in that it further comprises any one or more selected from the group consisting of polyphenols.
The functional food composition for preventing or alleviating symptoms of dementia according to claim 1, wherein the dementia is Alzheimer's dementia or vascular dementia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200052411A KR20210133603A (en) | 2020-04-29 | 2020-04-29 | Composition for preventing or treating dementia comprising grub as active component |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200052411A KR20210133603A (en) | 2020-04-29 | 2020-04-29 | Composition for preventing or treating dementia comprising grub as active component |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20210133603A true KR20210133603A (en) | 2021-11-08 |
Family
ID=78485906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200052411A KR20210133603A (en) | 2020-04-29 | 2020-04-29 | Composition for preventing or treating dementia comprising grub as active component |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20210133603A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050101537A (en) | 2002-12-24 | 2005-10-24 | 뉴로켐 (인터내셔널) 리미티드 | Therapeutic formulations for the treatment of beta-amyloid related diseases |
KR20120048105A (en) | 2010-11-05 | 2012-05-15 | 강원대학교산학협력단 | Pharmaceutical composition for the prevention and treatment of alzheimer's disease containing ursodeoxycholic acid ginkgo biloba extract |
-
2020
- 2020-04-29 KR KR1020200052411A patent/KR20210133603A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050101537A (en) | 2002-12-24 | 2005-10-24 | 뉴로켐 (인터내셔널) 리미티드 | Therapeutic formulations for the treatment of beta-amyloid related diseases |
KR20120048105A (en) | 2010-11-05 | 2012-05-15 | 강원대학교산학협력단 | Pharmaceutical composition for the prevention and treatment of alzheimer's disease containing ursodeoxycholic acid ginkgo biloba extract |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100425022B1 (en) | Ginseng extract and pharmaceutical composition containing it | |
JP4205188B2 (en) | Maillard reaction inhibitor | |
WO2007039976A1 (en) | Abnormal protein removing composition | |
TW200930389A (en) | Wolfberries and inflammation | |
KR102110902B1 (en) | Composition for anti-oxidation, anti-inflammation, anti-diabetes, whitening, anti-wrinkle, or anti-gout comprising extract of Ruby-S apple peel | |
KR20160087113A (en) | Cosmetics containing flowers | |
KR101425466B1 (en) | Leaf of Smilax china with Aspergillus species, method for preparing the same and use of the same | |
KR102022263B1 (en) | A composition comprising the fermented extract of Cinnamomum verum J. Presl, Ulmus davidiana var. japonica da and Acanthopanax sessiliflorum Seeman for preventing and treating benign prostatic hyperplasia | |
KR101789424B1 (en) | Medicinal-Herb Composition Comprising Chinese matrimony vine Proving Insomniac and the Method of Making the Same | |
CN107106624A (en) | Prevention, the composition for the mixed extract containing mulberries and fuling peel for improving or treating degenerative neural disease | |
KR20200052867A (en) | Composition for anti-inflammation, anti-diabetes, whitening, or inhibition of gout comprising extract of Ruby-S apple peel as an active ingredient | |
JP2018070570A (en) | Lindera plant extract | |
JP6055667B2 (en) | Collagen production promoter | |
KR100769302B1 (en) | Skin topical composition containing herbal extract for treating and improving scar pruritus | |
KR101023487B1 (en) | Arthritis prevention or treatment composition comprising a mixed herbal extract of Schisandra chinensis, golden and thawed skin as an active ingredient | |
KR20210048021A (en) | Antibacterial compositions comprising the citrus aurantium sinensis peel extract, the magnolia officinalis bark extract and polylysine | |
KR100471340B1 (en) | A new process for enhancing the efficacies of Ginseng | |
KR100569089B1 (en) | Composition having brain function and congnition enhancing activity | |
JP5976271B2 (en) | Lipase inhibitor and cosmetics, food / beverage composition and pharmaceutical composition containing the same | |
KR20210133603A (en) | Composition for preventing or treating dementia comprising grub as active component | |
KR20090007512A (en) | Emotional tea with spicy, sweety collagen blueberry vita green tea | |
KR100453542B1 (en) | Food additive and health foods containing Ginseng extract | |
JP2006265219A (en) | Diet composition | |
KR20160056655A (en) | Composition for inhibiting obesity comprising complex salt of baicalin and zinc | |
KR20100092922A (en) | A skin whintening cosmetic composition containing a oriental herb extracts mixture stabilized by nanoliposome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2021101000700; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20210319 Effective date: 20211111 |